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High density lipoprotein (HDL) or its apolipoproteins remove excess free cholesterol 
from cells to maintain cellular cholesterol homeostasis. This process, which is defined as 
reverse cholesterol transport (RCT), prevents the excessive cholesterol accumulating on 
the vessel wall and the development of atherosclerosis which causes significant morbidity 
and mortality in the developed societies. 
 
 In this study, apolipoprotein A-I (apoA-I) and methyl-β-cyclodextrin (MβCD) were used 
as cholesterol acceptors to investigate the mechanism of intracellular cholesterol 
trafficking and its effect on cholesterol efflux in human fibroblast. ApoA-I is the main 
protein of HDL that plays a key role in cholesterol efflux in vivo. It has been pointed out 
that apoA-I could bind directly to the exofacial face of the caveolae to facilitate FC 
desorption (Saito et al., 1997) and stimulate the translocation of intracellular cholesterol 
to the plasma membrane (Oram and Yokoyama, 1996) and subsequent enhancement of 
the efflux of intracellular cholesterol (Sviridov and Fidge, 1995). On the other hand, 
MβCD is a non-specific acceptor for cholesterol. It gets cholesterol from both caveolae 
and non-caveolae membrane domains. The results obtained in this study confirm that the 
kinetics of cholesterol effluxes to apoA-I or MβCD were clearly different in most cases, 
probably due to the fact that apoA-I and MβCD take cholesterol from different 
cholesterol pools. Here, the cholesterol was from two different cholesterol pools: plasma 
membrane derived cholesterol, which was directly labeled with 3H-cholesterol, and de 
novo synthesized cholesterol labeled by using 3H-acetate as the precursor.  
 
 xi 
Before cholesterol efflux, the cells were treated with different drugs which would affect 
the microtubules, the actin filaments, the Golgi apparatus and the ER, respectively, to 
examine if these subcellular organelles are involved in cholesterol trafficking and efflux. 
From the results of this study, it is known that caveolae is the key regulator of 
intracellular cholesterol trafficking and efflux. Disassembly of caveolae by cholesterol 
depletion markedly increased the cholesterol efflux to apoA-I. Disruption of actin 
microfilaments which are necessary for caveolae integrity also significantly enhanced 
cholesterol efflux. This result is a further support for the conclusion that caveolae are 
very important for cholesterol trafficking and efflux.  One of the other conclusions can be 
drown through this study is that Golgi apparatus appears to play a minor role in the 
movement of nascent cholesterol from ER to plasma membrane. It seems that 
microtubules, U18666A-inhibited cholesterol intracellular trafficking and ER-plasma 
membrane contacts did not affect cholesterol efflux at any significant level. However, 

















CHAPTER 1. INTRODUCTION 
1.1 Cellular cholesterol homeostasis and atherosclerosis 
1.1.1. Cellular cholesterol homeostasis  
 
Cholesterol is an essential component of cell-surface membranes. It functions to maintain 
the fluidity of cell membranes which separate the cell from its extracellular environment. 
It also provides the material for synthesis of bile acids and steroid hormones. At the 
cellular level, cholesterol homeostasis is maintained by regulated cholesterol uptake, de 
novo synthesis, intracellular transport and efflux.  
 
1.1.1.1. Cholesterol uptake 
 
Extrahepatic cells obtain cholesterol by endogenous synthesis and from circulating low 
density lipoprotein (LDL) particles, which are taken up via specific cell-surface receptors. 
Brown and Goldstein first demonstrated the presence of high-affinity LDL-binding sites 
on the surface of normal cells (Brown and Goldstein, 1986). LDL binds to LDL-receptors 
that cluster in clathrin-coated pits, specialized invaginations in the cell-surface, followed 
by formation of clathrin-coated vesicles, which subsequently become uncoated. 
Thereafter, a complex vesicular pathway selectively sorts both proteins and lipids that 
enter the lysosomes for subsequent metabolism, releasing unesterified cholesterol to other 
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intracellular sites and plasma membrane (Fielding and Fielding, 1997). The number of 
LDL-receptors expressed on the cell-surface is controlled by negative-feedback 
regulation involving the cells’ demand for cholesterol and membrane-bound transcription 
factors termed as sterol regulatory element-binding proteins (SREBPs)  (Horton et al., 
2002). When the concentration of cholesterol in the cell rises or demands for cholesterol 
are low, transcription of the LDL-receptor is suppressed (Brown and Goldstein, 1986; 
Horton et al., 2002); this slows down plasma LDL clearance and, consequently, the 
accumulating particles tend to undergo oxidative damage by free radicals. In contrast, 
when cellular cholesterol levels fall or demands for cholesterol are high, gene 
transcription is induced to enhance expression of LDL receptors and LDL clearance. 
These regulatory mechanisms serve to maintain a constant level of unesterified 
cholesterol, despite fluctuations in cellular requirements and exogenous supplies.  
 
The cell surface scavenger receptor class-B type I (SR-BI) functions as a HDL receptor 
that mediates nonendocytic, selective uptake of cholesterol. Unlike the classical LDL 
receptor pathway, in which the entire lipoprotein is internalized in clathrin-coated pits 
and degraded (Brown and Goldstein, 1986), HDL binds to SR-BI and the core cholesteryl 
ester (CE) is delivered to cross the plasma membrane without endocytosis and 
degradation of the entire HDL particle (Pittman et al., 1987). This two-step process is 
termed as ‘selective-uptake pathway’, with the first step being lipoprotein binding to the 
extracellular domain of SR-BI clustered in caveolae and the second step the transfer of 
lipids from HDL particle to cross the plasma membrane (Krieger, 1999). 
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1.1.1.2. Cholesterol synthesis 
Cholesterol synthesis is a complex biosynthetic process which begins with acetyl-CoA 
and involves more than 27 enzymes, many of which are located in the endoplasmic 
reticulum (ER) (Urbani and Simoni, 1990). The enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase catalyzes the rate-limiting reaction in cholesterol 
biosynthesis pathway (Brown and Goldstein, 1980). LDL-derived cholesterol suppresses 
intracellular cholesterol synthesis by depressing the activity of HMG-CoA reductase. 
 
1.1.1.3. Intracellular cholesterol distribution  
 
The correct cholesterol intracellular distribution is essential for many biological functions 
of mammalian cells. In the biosynthetic secretory pathway, cholesterol concentration is 
lowest in the ER. It increases through the Golgi apparatus, with the highest concentration 
in the plasma membrane (Liscum and Munn, 1999). 
 
Although cholesterol is synthesized in ER, cholesterol concentration in the ER is very 
low, comprising only 0.5-1% of total cellular cholesterol (Lange et al., 1999). However, 
cholesterol concentration in the ER membrane is crucial for cellular cholesterol 
homeostasis because many aspects of cholesterol regulation are under tight feedback 
control and are sensitive to the cholesterol concentration in the ER. 
 
The cholesterol content of the Golgi apparatus is intermediate between those of the ER 
and the plasma membrane (Mukherjee et al., 1998). It has been proposed that rafts rich in 
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cholesterol form in the Golgi apparatus and are selectively transported to the periphery 
from the trans-Golgi (Simons and Ikonen, 1997; Ikonen, 2001). 
 
In mammalian cells, the plasma membrane normally contains majority of cellular free 
cholesterol (FC) (Liscum and Munn, 1999). In several extrahepatic cell lines, including 
fibroblasts, only small part of plasma membrane cholesterol localized in exofacial leaflet 
of the membrane (Fielding and Fielding, 1997). FC first transported to caveolae is 
subsequently distributed to other plasma membrane domains, or released to extracellular 
acceptors (Fielding and Fielding, 1996; Smart et al., 1996; Uittenbogaard et al., 1998). 
FC in excess may be esterified by acyl coenzyme A:cholesterol acyltransferase (ACAT) 
and stored as CE droplets within the cytoplasm (Chang et al., 1997).  
 
Intracellular cholesterol trafficking is responsible to maintain the proper cellular 
cholesterol distribution and cholesterol efflux.  
 
1.1.1.4. Cholesterol efflux  
 
The removal of excess FC from cells by HDL or its apolipoproteins is important for 
maintaining cellular cholesterol homeostasis. Multiple mechanisms for cellular 
cholesterol efflux exist. Efflux of FC via aqueous diffusion occurs within all cell types 
but is inefficient (Phillips et al., 1987). Efflux of cholesterol is enhanced when SR-BI is 
present in the cell plasma membrane (Jig et al., 1997). Both diffusion-mediated and SR-
BI–mediated effluxes occur to phospholipid-containing acceptors (ie, HDL and lipidated 
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apolipoproteins); in both cases, the flux of cholesterol is bidirectional, with the direction 
of net flux depending on the cholesterol gradient. The ATP-binding cassette transporter 
A1 (ABCA1) mediates efflux of both cellular cholesterol and phospholipid. In contrast to 
SR-BI–mediated flux, efflux via ABCA1 is unidirectional, occurring to lipid-poor 
apolipoproteins. The details of these three mechanisms will be discussed further in 




Atherosclerosis causes significant morbidity and mortality in the developed societies. The 
magnitude of this problem is profound, as atherosclerosis claims more lives than all types 
of cancer combined. Although currently it is a problem of the developed world, the 
World Health Organization predicts that global economic development could lead to an 
epidemic of atherosclerosis in the developing countries that acquire Western life style. 
Atherosclerosis is characterized by the accumulation of cholesterol deposits in 
macrophages in large- and medium-size arteries. Macrophages internalize modified 
lipoproteins and cell debris and this process is not regulated by cholesterol. In contrast to 
other cells, macrophages accumulate lipid in cell bodies. Released from lysosomes, FC is 
transferred to the ER either directly or indirectly via the plasma membrane. In the ER, 
cholesterol is esterified by ACAT to protect the cell from the cytotoxicity of excess 
unesterified cholesterol (Chang, 1997). CEs have lower water solubility than cholesterol 
and appear as cytosolic lipid droplets. The lipid laden macrophages have foamy shape 
and are termed as foam cells which gradually impinge on the vessel lumen and hinder 
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blood flow. This process can last for decades until an atherosclerotic lesion, leading to 
thrombosis and compromised oxygen supply to target organs such as the heart and brain. 
The loss of heart and brain function as a result of reduced blood flow is termed as heart 
attack and stroke, respectively (Stocker and Keaney, 2004). 
  
 
1.2. Reverse cholesterol transport (RCT): Function of HDL 
 
RCT originally discovered by Glomset (Glomset, 1968) is a pathway transporting excess 
cholesterol from extrahepatic cells and tissues to the liver for the synthesis of bile acids 
and subsequent excretion from the body. By reducing the accumulation of cholesterol in 
the wall of arteries, RCT may prevent development of atherosclerosis. Approximately 10 
mg cholesterol per kilogram body weight is synthesized by extrahepatic tissues every day 
and must be transferred to the liver for effective catabolism (Dietschy et al., 1993). HDL 
particles are thought to play the key role in this protective system against atherosclerosis.  
 
The process of RCT is complex. Lipid-poor apoA-I mediates cholesterol efflux from cells. 
Cholesterol is converted to CE by enzyme lecithin-cholesterol acyltransferase (LCAT) 
within HDL. CEs are transferred from HDL to apolipoprotein B–containing lipoproteins 
by cholesteryl ester transfer protein (CETP). Then HDL CEs are used for bile acids 
biosynthesis in the liver (Daniel, 2003). Preβ1-HDL, a discoid lipid-poor particle, is the 
initial acceptor of cellular cholesterol (Sviridov and Nestel, 2002). It may be originated 
mainly from the surface components of hydrolyzed triglyceride-rich lipoproteins in the 
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blood stream. Accumulation of cholesterol into the particles transforms the pre β1-HDL 
into larger spherical lipoprotein particles, namely, pre β2-HDL, which is the substrate for 
LCAT. FC on the surface of pre β2-HDL is converted to more lipophilic CEs by LCAT, 
leading to an expansion of particles into spherical shape.  These particles acquire more 
cholesterol from preβ-HDL (Sasahara et al., 1998) and are transformed into larger α2-
HDL and α1-HDL. The HDL particles finally transfer cholesterol to the liver by at least 
two distinct processes: (i) HDL particles dock to the SR-BI receptors which express on 
the cell membrane of the hepatocyte; (ii) HDL particles exchange CEs for triglyceride 
from remnant particles and LDL, a process driven by the action of CETP. Finally, 
triglyceride and phospholipids are hydrolyzed by hepatic lipase. Particles are remodeled 
into smaller α3-HDL particles and lipid-free apoA-I, which in turn are rapidly re-lipidated 
by cellular cholesterol and phospholipids to form new preβ1-HDL. As discussed above, 
HDL cholesterol is finally delivered to the liver. Hepatic cholesterol can then be excreted 
from the body either as FC directly or after conversion to bile acids. The liver is the only 
organ which can substantially influence net excretion of cholesterol from the body and 
cholesterol delivered by lipoproteins is a primary source of substrates for biliary lipid 
secretion as bile acids and cholesterol (Angelin, 1995).  
 
An inverse relationship between HDL levels and the incidence of atherosclerotic 
coronary artery disease has been supported by numerous epidemiological studies. It 
seems that HDL cholesterol is associated with protection against coronary artery disease 
because HDL levels indicate the efficiency of RCT. Many of the factors that increase 
HDL level are antiatherogenic, due to the complex interrelationships of HDL and 
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triglycerides-rich lipoprotein metabolism and other metabolic pathways. Each 
interposition influencing HDL will have to be prospectively evaluated (Tall, 1990). 
 
1.3. Pathways mediating cellular cholesterol efflux 
 
Cholesterol efflux, in which excess cellular FC is released from cells to HDL particles, is 
the first step of RCT. It is a complex process and multiple mechanisms exist, depending 
on the particular cell type and its metabolic state, different membrane cholesterol pools 
and the nature of the acceptor particles. . There are 3 known mechanisms of FC efflux: (1) 
aqueous diffusion, (2) SR-BI-mediated FC efflux, and (3) ABCA1-mediated efflux. Each 
mechanism and its relative importance will be discussed briefly here (Yancey et al., 
2003). 
 
1.3.1. Aqueous diffusion 
 
The simplest and most basic mechanism for cellular cholesterol efflux is aqueous 
diffusion in which individual cholesterol molecules desorb from the plasma membrane, 
diffuse through the aqueous phase and are captured by phospholipids containing acceptor 
particles. This process is passive and driven by the cholesterol concentration gradient 
(Johnson et al., 1991).  
 
The FC transfer rate from cells to medium is influenced by both cell and acceptor 
properties. At low acceptor concentrations, the FC transfer rate is dependent on the 
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frequency of diffusion mediated collisions between cholesterol molecules and acceptor 
particles. At high acceptor particle concentrations, the desorption of cholesterol 
molecules from the surface of cells becomes the rate-limiting step; there is a high 
activation energy acquired for this step, and cholesterol transfer rates are strongly 
temperature-dependent (Phillips et al., 1987). 
 
The rate of FC efflux via aqueous diffusion is highly dependent on the structure of the 
acceptor particle. The size of the acceptor particle is important because it affects the 
diffusion-mediated collisions with cholesterol molecules on the cell surface. Large 
particles are inefficient acceptors due to the limited access to the cell surface (Rothblat et 
al., 1999). If the distance between the FC donor and acceptor is very small, the time 
required for diffusion between them will decrease obviously (Fielding and Fielding, 
2001). In contrast, two other factors will slow the simple diffusion of FC from cell 
surface. Majority of FC in the plasma membrane is in the cytofacial leaflet of the bilayer 
(Fielding and Fielding, 1997). The rate of cholesterol exchange between the cell 
membrane leaflets is relatively slow compared to FC efflux (Raggers et al., 2000). As a 
result, in the absence of other factors, only the exofacial pool of plasma membrane FC 
(typically 3-5% of total FC) will contribute directly to simple diffusion. Secondly, the 
cell surface is bounded by an ‘unstirred water layer’ which forms a significant diffusion 
barrier. The extent of ‘unstirred water layer’ is inversely proportional to the solute 
diffusion coefficient (Pohl et al., 1998).  
 
1.3.2. SR-BI mediated cholesterol efflux 
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Early studies showed that different kinds of cells exhibit significantly different 
cholesterol efflux rates to phospholipids containing acceptors (Rothblat and Phillips, 
1982) due to several possible reasons, such as variability in the fluidity or cholesterol 
content of the plasma membrane, in the thickness or composition of the extracellular 
matrix, which might affect the access of cholesterol acceptors to the plasma membrane, 
or in different expression levels of lipoprotein receptor in the plasma membranes of 
different cell types (Rothblat et al., 1999). Subsequent studies have shown that these 
differences are attributable to different expression levels of SR-BI (Ji et al., 1997; Jian et 
al., 1998). This conclusion is supported by the experiment that efflux is accelerated from 
COS-7 cells transiently transfected with SR-BI compared with efflux from control COS-7 
cells (de la Llera-Moya et al., 1999). 
 
Besides stimulating the efflux of FC, expression of SR-BI also drives the influx of FC. 
Thus, movement of FC via SR-BI is bidirectional and the net movement of FC via SR-BI 
depends on a preexisting cholesterol concentration gradient (Kellner-Weibel et al., 2000;  
de la Llera-Moya et al., 2001). 
 
The detailed mechanism by which SR-BI facilitates the bidirectional flux of FC is not 
very clear. Although not proven, it is often assumed that SR-BI facilitates the diffusion 
mechanism of FC flux. Binding of the acceptor particles in close apposition to SR-BI 
could possibly enhance the aqueous diffusion by concentrating the acceptor particles at 
the cell surface. However, it has been proven that high-affinity binding to cell surface 
receptors alone is not sufficient to stimulate the efflux of FC, because the expression of 
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CD36 in COS-7 cells markedly enhances the high-affinity binding of HDL but does not 
increase efflux. The data indicate that SR-BI changes the plasma membrane cholesterol 
organization and then enhances the bi-directional cholesterol flux between cells and 
extracellular acceptors (de la Llera-Moya et al., 1999). The presence of SR-BI on the 
plasma membrane creates an environment whereby the rate of exchange of FC molecules 
is increased. In such a situation the net movement of FC between cell surface and 
acceptor articles is not influenced by SR-BI. Instead, the net movement of FC is decided 
by the FC gradient that exists between the acceptors and the cell surface. It is likely that 
the SR-BI-induced changes in plasma membrane organization involve caveolae and/or 
lipid rafts (Rothblat et al., 1999) because in some cell types, SR-BI is localized to 
caveolae and lipid rafts, areas of the membrane that are rich in both cholesterol and 
sphingolipids (Babitt et al., 1997; Graf et al., 1999). 
 
1.3.3. ABCA1 mediated cholesterol efflux 
 
1.3.3.1. Discovery of ABCA1 
 
The discovery of ABCA1 came from the study of the patients with Tangier disease, a rare 
recessive disorder.  These patients present with very low levels of lipid-free apoA-I and 
HDL, accumulation of CE in macrophage-rich tissues and large orange tonsils 
(Fredrickson, 1964). In the cholesterol enriched fibroblasts and macrophages from 
patients with Tangier disease, efflux of cholesterol and phospholipid to lipid-free apoA-I 
is markedly reduced but efflux to HDL as acceptors is normal (Francis et al., 1995). Since 
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apoA-I is unable to sequester cholesterol and phospholipid to generate discoidal pre-β-
HDL, the apoA-I protein is rapidly degraded (Knight, 2004).  
 
In 1999, several groups using different strategies identified ABCA1 as the defective gene 
in Tangier disease patients, and proposed that the protein controls the transfer of both 
cholesterol and phospholipid to apoA-I, the initial step in HDL synthesis (Brooks-Wilson 
et al., 1999; Bodzioch et al., 1999; Rust et al., 1999). 
  
ABCA1 belongs to the ATP-binding cassette (ABC) family of genes encoding 
transmembrane proteins which have common structural characters. Each member of the 
ABC family is believed  to transport a specific set of molecules (e.g. ions, amino acids, 
proteins, sugars, phospholipids and a range of drugs) across the plasma membrane, as 
well as intracellular membranes of the ER and mitochondria using ATP (Dean et al., 
2001). Each transporter  contains either one or two copies of structural elements:
 
a 
hydrophobic region of six transmembrane domains and a hydrophilic cytosolic ATP-
binding cassette, comprising two conserved peptide motifs (Walker A and Walker B 
motifs) and a unique amino acid signature sequence between each Walker motif (Walker 
et al., 1982). ABCA1 contains two of these units, covalently linked by a highly 
hydrophobic segment, which is assumably an essential element for the translocation of 
lipids. 
 
1.3.3.2. Mechanism of ABCA1 meditaed cholesterol efflux: ApoA-I – ABCA1 
interactions 
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In contrast to aqueous diffusion and SR-BI–mediated FC flux, the cholesterol efflux 
mediated by ABCA1 is unidirectional and net efflux of cellular FC would always occur 
via this mechanism independent of the cholesterol gradient. The preferred cholesterol 
acceptor for ABCA1 is lipid-poor apolipoproteins especially apoA-I. There has been 
considerable controversy over the mechanism of action of ABCA1, particularly in 
relation to the binding of acceptor molecules.  
 
ABCA1-mediated lipid (cholesterol and phospholipid) efflux requires an acceptor 
apolipoprotein containing an amphipathic helix, such as apoA-I, apoA-II or apoE. It is 
also known that ABCA1 activity induces the formation of novel structures that protrude 
from the plasma membrane and bind apolipoproteins (Lin and Oram, 2000). Probably the 
phosphatidylserine exofacial flopping generates a biophysical microenvironment required 
for the docking of apoA-I at the cell surface. This has led to the hypothesis that apoA-I 
binds to a region of the membrane modified by ABCA1, a conclusion supported by the 
different lateral mobilities of ABCA1 and apoA-I on the cell surface (Chambenoit et al., 
2001). Subsequent study pointed out that a cytotoxic pool of FC, which is located in the 
plasma membrane, is readily available for efflux to apoA-I, and ABCA1 may be involved 
in the removal of cytotoxic cholesterol (Kellner-Weibel et al., 2003). On the other hand, 
chemical cross-linking and immunoprecipitation analysis showed that apoA-I binds 
directly to ABCA1 (Wang et al., 2000), and natural mutations in the extracellular loops 
of ABCA1 extinguish cholesterol efflux and direct interaction of ABCA1 and apoA-I. 
Furthermore, a specific mutation in the first loop of ABCA1 (W590S) reduced 
cholesterol efflux but not cross-linking activity, indicating that acceptor binding is 
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necessary, but not sufficient, for cholesterol efflux (Fitzgerald et al., 2002). Recently, a 
novel, highly conserved motif (VFVNFA) of the ABCA1 C terminus was identified. This 
conserved motif was required for lipid efflux and alteration of this motif eliminated its 
binding of apoA-I (Michael et al., 2004). 
 
Since HDL cholesterol and phospholipid levels are very low in plasma from Tangier 
disease patients and ABCA1 is identified as the defective gene in those patients, it was 
initially proposed that ABCA1 transport both these lipids across the plasma membrane 
directly. Upon ATP-binding and hydrolysis, cholesterol and phospholipids were rapidly 
flipped from the inner to the outer leaflet of the membrane bilayer, to be sequestered by 
lipid-poor apoA-I. 
 
However, later study suggests that cholesterol is not the substrate for ABCA1 and is 
effluxed from cells via a two-step mechanism. When FC efflux from cells expressing 
high levels of ABCA1 was inhibited, phospholipid efflux to apoA-I still occurred. 
Moreover, when this conditioned media containing phospholipids-apoA-I complexes was 
transferred to ABCA1-deficient cells, it stimulated efflux of FC, but not phospholipids 
(Fielding et al., 2000). Other researchers showed that ABCA1 did not bind cholesterol 
directly and apoA-I binding to ABCA1 was closely associated with phospholipid 
translocation, but not FC efflux (Wang et al., 2001). These experiments indicate a two-
step mechanism for FC efflux. Firstly, ABCA1 actively transfers phospholipids (PLs) 
across the membrane to lipid-poor apoA-I; this generates discoidal phospholipid-apoA-I 
complexes, which can acquire FC subsequently. So ABCA1 is believed to function 
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indirectly as a cholesterol efflux regulatory protein to promote preβ1-HDL formation 
(Owen and Mulcahy, 2002). In recent study, the author pointed out that apoA-I binds to 
ABCA1 which induces the formation of the perturbed PL bilayer by its PL transport 
activity in the first step. The hydrophobic α-helices in the C-terminal domain of apoA-I 
insert into the region of the perturbed PL bilayer and induce the second step of lipidation 
of apoA-I and formation of nascent HDL particles (Vedhachalam et al., 2004).  
 
On the other hand, another hypothesis has been proposed to explain the mechanism 
through which ABCA1 plays a role in cholesterol efflux. In the mechanism named 
membrane solubilization phospholipids and cholesterol are mobilized simultaneously in 
whatever proportions they are present by lipid free apoA-I as discrete units (Gillotte et al., 
1998; 1999). But the precise mechanism has not been elucidated.  
 
1.3.3.3. Regulation of ABCA1 expression 
 
Transcription of the ABCA1 gene and cell-surface expression of ABCA1 protein are 
tightly regulated by many metabolites, including sterols, cAMP, cis-retinoic acid, 
peroxisome proliferator-activated receptor (PPAR) agonists, and interferon γ (IFN- γ).  
 
Cholesterol loading is known to increase ABCA1 mRNA and protein level. This increase 
is reversed when cellular cholesterol is removed by incubation with HDL (Langmann et 
al., 1999). This effect is thought to be mediated by the stimulation of liver X receptor 
(LXR) nuclear hormone receptor that is activated by oxysterol ligands. Physiological 
LXR ligand 22-(R)-hydroxycholesterol and LXR selective agonist TO-901317 increase 
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ABCA1 mRNA level by more than 3-fold. This enhancement is absent in peritoneal 
macrophages isolated from LXRα and LXRβ knockout mice (Repa et al., 2000).  
 
Previous study illustrated that RAW264 macrophages treated with 8-bromo-cAMP 
showed parallel increases in ABCA1 mRNA and protein levels, incorporation of ABCA1 
into the plasma membrane, binding of apoA-I to cell surface ABCA1 and apoA-I-
mediated cholesterol efflux (Oram et al., 2000). However, the regulatory motif in the 
human promoter that binds cAMP and activates the ABCA1 gene has yet to be identified. 
In normal macrophages, PPARα and PPARγ agonists increase ABCA1 mRNA 
expression and apoA-I mediated cholesterol efflux, whereas no effects are observed in 
macrophages from patients with Tangier disease (Chinetti et al., 2001). LXRα mRNA 
was induced also by these agonists. Furthermore, the addition of both PPAR and LXRα 
activators had an additive effect on induction of ABCA1 expression. However, no 
functional PPAR response element has been identified in the ABCA1 promoter. It 
appears that PPAR agonists may indirectly modulate ABCA1 gene expression by 
activation of the LXRα pathway and illustrate a complex interaction between PPARα, 
PPARγ and LXRα in the cellular regulation of ABCA1 gene expression. 
 
In contrast, IFNγ reduces ABCA1 expression, thereby reducing apoA-I-mediated 
cholesterol and phospholipid efflux in mouse peritoneal macrophages and foam cells 
(Panousis and Zuckerman, 2000).  This suggests that by decreasing cellular cholesterol 
efflux through pathways that include up-regulation of ACAT and down-regulation of 
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ABCA1, IFNγ may facilitate the conversion of macrophages to foam cells, promoting the 
progression of atherosclerosis. 
 
 
1.4. Intracellular cholesterol trafficking and cholesterol efflux 
 
1.4.1. From lysosome to plasma membrane and the cell interior 
 
An important cholesterol source is LDL which is internalized and delivered to lysosomes. 
CEs are carried largely in the core compartment of LDL particles, after its hydrolysis, FC 
is rapidly released from lysosomes and appears in the plasma membrane (Brasaemle and 
Attie 1990; Johnson et al., 1990). LDL-cholesterol transport from lysosomes to plasma 
membrane is inhibited by U18666A but not affected by agents that disrupt the 
cytoskeleton (Liscum, 1990). The Niemann-Pick C1 (NPC1) protein is the key regulator 
responsible for exit of LDL cholesterol from lysosomes. Cells with defective NPC1 
accumulate unesterified cholesterol in lamellar bodies derived from lysosomes and 
exhibit markedly impaired rates of esterification of LDL cholesterol (Pentchev et al., 
1994). NPC cells are defective in the delivery of lysosomal cholesterol to the plasma 
membrane (Neufeld et al., 1996). Consistent with the findings, NPC1 overexpression 
increases the rate of delivery of endosomal cholesterol to the plasma membrane, 
providing further support for the role of NPC1 in this trafficking pathway (Millard et al., 
2000). However, the details about function of NPC1 have not yet been pinpointed. The 
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NPC1 protein may function in cholesterol modulated late endocytic vesicular transport 
(Blanchette-Mackie, 2000).  
 
LDL-cholesterol is not only mobilized to the plasma membrane but is also transported to 
the ER, where cholesterol may become esterified by ACAT (Liscum and Munn, 1999). 
This process is inhibited by hydrophobic amines, such as U18666A (Liscum and Faust, 
1989), imipramine (Rodriguez-Lafrasse et al., 1990) and progesterone (Butler et al., 
1992). This latter pathway is energy dependent (Skiba et al., 1996) but plasma membrane 
independent (Underwood et al., 1998). 
.  
1.4.2. From ER to plasma membrane 
 
The nascent cholesterol synthesized in ER is transferred to plasma membrane rapidly 
(half time of ~10 min) (DeGrella and Simoni, 1982; Kaplan and Simoni, 1985). The 
transport is ATP-dependent and inhibited at 15°C. Treatment with brefeldin A, which 
disrupts Golgi apparatus, does not affect nascent cholesterol transport from ER to plasma 
membrane (Urbani and Simoni, 1990). This raises the possibility that nascent cholesterol 
is transported to plasma membrane via a pathway bypass Golgi apparatus. When 
cholesterol arrives in the plasma membrane, it is found first in the caveolae. Most of the 
cholesterol is transported out of the membrane if native plasma is present (Fielding and 
Fielding, 1995). In the absence of extracelluar lipoproteins, cholesterol migrates to the 
surrounding non-caveolae membrane (Smart et al., 1996).  
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1.4.3. From plasma membrane to cell interior  
 
Plasma membrane cholesterol is constitutively transported into the cell interior and 
returned to the cell surface rapidly (Lange et al., 1993). This movement of plasma 
membrane cholesterol to cell interior is inhibited by different reagents. Some of these, 
such as hydrophobic amines U18666A (Härmälä et al., 1994), sphingosine (Härmälä et 
al., 1993) and progesterone (Lange, 1994), inhibit several intracellular cholesterol 
transport pathways. Some drugs which disrupt cellular cytoskeleton also inhibit 
cholesterol from plasma membrane to ER. This indicates that intact intermediate filament 
is important to this pathway (Evans, 1994). These results induce the speculation that the 
movement of plasma membrane cholesterol to cell interior is mediated by vesicular 
transport. However, such intermediate has not been fully identified (Liscum and Munn, 
1999).  
 
1.4.4. Function of `caveolae    
 
Caveolae are FC-rich, clathrin-free plasma membrane invaginations with a characteristic 
diameter of 50 to 100 nm (Smart et al., 1999). The core membrane structure of caveolae 
is enriched in cholesterol, gangliosides, ceramide, diacylglycerol (Liu and Anderson, 
1995), phosphatidylinositol diphosphate (Pike and Casey, 1996) and the integral 
membrane protein caveolin which is a 22-kDa cholesterol binding protein (Murata et al., 
1995). The involvement of caveolin in cholesterol transport is consistent with several 
previous observations. (i) The nascent cholesterol synthesized in ER first appears in the 
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caveolae domain of the plasma membrane (Smart et al., 1996). (ii) Progesterone, which 
blocks cholesterol transport, causes caveolin accumulation in the lumen of the ER (Smart 
et al., 1996).  (iii) Oxidase treatment of caveolae cholesterol causes caveolin to dissociate 
from plasma membrane and redistribute to intracellular vesicles that co-localize with 
Golgi apparatus markers (Smart et al., 1994). (iv) The caveolin mRNA levels and 
caveolin expression are very sensitive to the FC content of the cell. An increase in LDL–
FC internalization was associated with proportional cellular FC and upregulation of 
caveolin (Fielding et al., 1997). On the other hand, cholesterol efflux from HepG2/cav 
cells, which are transfected with human caveolin-1 and then express caveolin-1 mRNA, a 
high abundance of caveolin-1 protein, and the formation of caveolae on the plasma 
membrane, is 45% higher than that from parent HepG2 cells when human apoA-I was 
used as acceptor (Fu et al., 2004).  
 
Depletion of caveolar FC with cyclodextrin (CD) led to down-regulation of caveolin 
mRNA and cell surface protein levels (Hailstones et al., 1998). There is evidence 
suggesting that caveolae efflux cellular cholesterol to HDLs, the principal acceptor of 
cellular cholesterol in the RCT pathway (Fielding and Fielding, 1995). More recently, 
HDL and caveolin-1 were proved co-localized in caveolae by immunoelectron 
microscopy in endothelial cells loaded with cholesterol (Chao et al., 2003). However, the 
direct evidence about this process is absent and the data available remain controversial, 




1.4.5. Function of Golgi apparatus 
It is now recognized that Golgi apparatus plays a key role in cholesterol sorting and 
trafficking. The first noticeable evidence for Golgi involvement in cholesterol movement 
was shown by freeze-fracture electron microscopy using filipin as a probe for FC (Coxey 
et al., 1993). After addition of LDL to cultured fibroblasts for 24 h, cholesterol is 
enriched within specific compartments of the Golgi. This cholesterol enrichment in Golgi 
apparatus was seen even in NPC fibroblasts. It was suggested that the Golgi was involved 
in LDL cholesterol transport from lysosomes to the plasma membrane. Treatment of cells 
with brefeldin A which can disrupt Golgi apparatus resulted in enhanced cholesterol 
delivery to ACAT. This could be due to LDL-cholesterol destined for the plasma 
membrane being redistributed to ER by blocking the Golgi dependent pathway (Neufeld 
et al., 1996). Subsequent studies confirmed the finding that an intact Golgi apparatus is 
not necessary for the flow of LDL-cholesterol to the ER. The LDL-cholesterol movement 
to ACAT is normal even when the Golgi apparatus is severely disrupted by brefeldin A 
(Underwood et al., 1998). It is still unclear whether the Golgi apparatus is involved in the 
plasma membrane-independent route of LDL-cholesterol transport to the ER.  
 
There were results suggesting that newly synthesized cholesterol was transported from 
ER to plasma membrane via a vesicular system (Kaplan and Simoni, 1985). However, an 
efficient alternate pathway for nascent cholesterol movement was proposed when severe 
disruption of Golgi apparatus did not alter the kinetics of cholesterol arrival at the plasma 
membrane (Urbani and Simoni, 1990).  
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1.5. Aims of this project 
 
Cholesterol is an essential component of cellular membranes. Cholesterol homeostasis is 
maintained by regulating cholesterol uptake and de novo synthesis, intracellular transport 
and efflux. Many diseases are related to defective cholesterol metabolism such as 
coronary heart disease, Tangier disease and Alzheimer's disease. The mechanisms 
involved in maintaining cholesterol homeostasis are very complicated and not clear yet. 
The aim of this study is to investigate the effect of intracellular cholesterol trafficking on 
cholesterol efflux in human fibroblast. I labeled cellular cholesterol through two different 
ways, directly incubating cells with 3H-cholesterol or incubating cells with 3H-acetate 
which will be converted to 3H-cholesterol via do novo synthesis route. The labeled cells 
were treated with different drugs which would affect microtubule, actin network, Golgi 
apparatus or ER to test if these factors contribute to cholesterol trafficking and efflux. 
Cholesterol efflux was performed using lipid free apolipoprotein A-I or methyl-β-
cyclodextrin (MβCD) as acceptors. Apolipoprotein A-I is the major protein component of 
HDL, while MβCD is one of the simplest and commonly used extracellular cholesterol 
acceptors. It contains cyclic oligosaccharides that are believed to be able to dissolve 
lipids in their hydrophobic core. The significance of ABCA1 expression and intracellular 









The following reagent was purchased from Ajax Chemicals Pty Limited (9 short 
street, Auburn, N.S.W. 2144, Australia) 
Anhydrous Diethyl Ether 
 
The following reagent was purchased from Amersham (Amersham Biosciences UK 
Limited, Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA, England) 
BCS Scintillation Cocktail 
 
The following reagents were purchased from BioRad (Bio-Rad Laboratories, 2000 
Alfred Nobel Drive, Hercules, California 94547) 
Rabbit Anti-Goat IgG (H+L)-HRP Conjugated, Goat Anti-Mouse IgG (H+L)-HRP 
Conjugated, Prestained Broad Range Precision ProteinTM Standards, Ammonium 
Persulfate, Acrylamide (N,N’-Methylenbisacrylamid Electrophoresis Purity reagent)/Bis 
Solution, Electrophoresis Purity Reagent Bromophenol Blue, RC DC Protein Assay Kit 
(including DC Protein Assay Reagent A, DC Protein Assay Reagent B, DC Protein Assay 
Reagent S, RC Protein Assay Reagent I, RC Protein Assay Reagent II) 
 
 24 
The following reagent was purchased from Calbiochem (EMD Biosciences, Inc., 
10394 Pacific Center Court, San Diego, CA 92121) 
Fluor saveTM Reagent 
 
The following reagent was purchased from Cambrex (Cambrex Corporation, One 
Meadowlands Plaza, East Rutherford, New Jersey 07073) 
 EMEM (Minimum Essential Medium Eagles) 
 
The following reagent was purchased from Chemicon International (28820 Single 
Oak Drive, Temecula, CA 92590) 
Re-Blot Plus Strong Solution 
 
The following reagent was purchased from Duchefa Biochemie (A. Hofmanweg 71, 
2031 BH Haarlem, the Nethelands) 
polysorbate 20 (TWEEN 20) 
 
The following reagent was purchased from Epicentre (726 Post Road, Madison, WI 
53713 USA) 
Brefeldin A  
 
The following reagent was purchased from Hayman Limited (Eastways Park, 
Witham, Essex, CM8 3YE England) 
Ethyl Alcohol A.R. Quality 
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The following reagent was purchased from HyClone (Hyclone, 925 West 1800 South, 
Logan, UT 84321) 
Fetal bovine serum 
 
The following reagents were purchased from Invitrogen (Faraday Avenue, Carlsbad, 
California U.S.A.) 
Glutamine, Penicillin-streptomycin, Goat Serum 
 
The following reagent was purchased from Intracel (Intracel, 93 Monocacy 
Boulevard, Unit A8, Frederick, MD 21701) 
Fetal Bovine Lipoprotein Deficient Serum 
 
The following reagents were purchased from J. T. Baker (Mallinckrodt Baker, Inc., 
222 Red School Lane, Phillipsburg NJ 08865 U.S.A.)  
Tris (Base), Chloroform  
 
The following reagent was purchased from Mallinckrodt Chemicals (Mallinckrodt 
Laboratory Chemicals, A Division of Mallinckrodt Baker, Inc., 222 Red School 
Lane, Phillipsburg, NJ 08865) 
Anhydrous Methyl Alcohol 
 
The following reagents were purchased from Merck (Merck KGaA, Frankfurter Str. 
250, 64293 Darmstadt, Germany) 
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Triton® X-100, Glycin, Sodium Hydroxide Pellets, Acetic Acid, n-Hexan, Isopropanol, 
25 TLC aluminium sheets 20×20cm Silica Gel 60 F254, 3β-[2-(diethylamino) ethoxy] 
androst-5-en-17-one (U18666A) 
 
The following reagents were purchased from Molecular Probes (Eugene, OR 97402-
0469, 29851 Willow Creek Road, Eugene, OR 97402, United States) 
Alexa Fluor® 488 Goat anti-mouse IgG, Jasplakinolide,  
 
The following item was purchased from Pall Corporation (2200 Northern Boulevard, 
East Hills, NY 11548) 
Bio TraceTM PVDF(polyvinglidene fluoride) Transfer Membrane 
 
The following reagents were purchased from Perkin Elmer (Perkin Elmer® Life and 
Analytical, Science, Boston, MA, USA) 
[1,2-3H(N)]-Cholesterol, [3H]-Acetic Acid Sodium Salt 
 
The following reagents were purchased from Pierce (Pierce Biotechnology, Inc., 
Rockford, IL) 
Super Signal West Femto Maximum Sensitivity Substrate, Super Signal West Pico 
Chemiluminescent Substrate, Bond-BreakerTM TCEP solution, CL-X PosureTM Film, 
8×10 inches, Clear Blue X-Ray Film 
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The following reagent was purchased from Roche Diagnostics (F. Hoffmann-La 
Roche Ltd, Diagnostics Division, Grenzacherstrasse 124, CH-4070 Basel, 
Switzerland) 
Complete EDTA-free Protease inhibitor cocktail tablets, 
 
The following reagents were purchased from Senta Cruz Biotechnology (2145 
Delaware Avenue, Santa Cruz, Califomia 95060) 
Anti-ABCA1, goat polyclonal IgG 
 
The following reagents were purchased from Sigma (Sigma-Aldrich, 3050 Spruce St., 
St. Louis, MO 63103) 
Trypsin-EDTA solution, Apolipoprotein A-I, DMSO (Methyl sulfoxide), Monoclonal 
anti-β-Actin clone AC-74, TO-901317, Phosphatidylinositol-specific Bacillus cereus 
Phospholipase C, Deep Blue Dyed Latex Beads, Methyl-β-cyclodextrin (MβCD), 
TEMED (N,N,N’,N’-Tetramethyl-Ethylenediamine), Heptane, Nocodazole, Cytochalasin 
D, Lauryl sulfate (SDS), Paraformaldehyde (PFA) 
 
The following reagent was purchased from Spectrum Chemical Mfg. Cotp. (S. San 
pedro Street, Gaedena, California) 
Hydrochloric Acid 
 
The following reagent was purchased from Singapore Oxygen Air Liquid Pte Ltd 
(Soxal, Singapore) 
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Carbon dioxide (CO2), Pure Liquid Nitrogen 
  
2.1.2. Media and buffers 
 
2.1.2.1. Reagents for cell culture 
 
Complete EMEM medium 
Minimum Essential Medium Eagles supplemented with 15% (v/v) uninactivated fetal 
bovine serum and a mixture of L-glutamine (2 mM, final concentration, the same below), 
penicillin (100 unit/ml) and streptomycin (100 µg/ml) 
Delipidated EMEM medium 
Minimum Essential Medium Eagles supplemented with 7.5% (v/v) uninactivated 
lipoprotein deficient serum (LPDS) and a mixture of L-glutamine (2 mM, final 
concentration, the same below), penicillin (100 unit/ml) and streptomycin (100 µg/ml)   
Frozen medium 
Minimum Essential Medium Eagles supplemented with 40% (v/v) uninactivated fetal 
bovine serum with 10% DMSO and 2mM L-glutamine 
Lysis buffer 
50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X-100,  
Serum-free EMEM medium 
Minimum Essential Medium Eagles supplemented with L-glutamine (2 mM, final 
concentration, the same below), penicillin (100 unit/ml) and streptomycin (100 µg/ml)   
PBS 
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1.76 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 9 mM KCl, pH 7.4 
Trypsin-EDTA 
0.05% trypsin and 0.02% EDTA   
 
2.1.2.2. Reagents for Western Blotting 
 
4×Resolving gel buffer 
1.5 M Tris-HCl, pH 8.8 
4×Stacking gel buffer 
0.5 M Tris-HCl, pH 6.8 
5×Loading buffer (for 10 ml stock) 
1 g SDS, 5 g sucrose, 0.01 g Electrophoresis purity reagent bromophenol blue, 3.125 ml 1 
M Tris-HCl (pH6.8), 1 ml TCEP, 3 ml distilled water, mixed well by stirring overnight 
10×Transfer buffer stock 
30.3 g Tris and 144.13 g glycine in 1 liter distilled water. 
Blocking buffer 
5% Anlene skimmed milk in TBS 
5×Running buffer 
15.15 g Tris-HCl, 72 g glycine and 5 g SDS in 1 liter distilled water 
TBS  
6.075 g Tris and 8.766 g NaCl dissolved in 1 liter distilled water, pH adjusted to 7.5  
TBST 
0.1% TWEEN 20 in TBS buffer 
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Transfer buffer 
100 ml 10×transfer buffer topped up to 800 ml with distilled water, mixed well, then 200 
ml methanol added 
                   
2.1.3. Instruments and other general consumables 
 
The instruments and general consumables used in this work include BECKMAN LS6000 
Scintillation Counter (Beckman Coulter, Inc., 4300 N. Harbor Boulevard, Fullerton, CA), 
Biological Safety Cabinet Class II (Gelman Science Inc., Washtenaw County Circuit 
Court), CO2 Incubator (Heraeus Kulzer Australia Pty Ltd., Unit 3, 4 Gibbes Street, 
Chatswood, Australia), Dry-Bath (Medical Research Council, 20 Park Crescent, London 
W1B 1Al, UK), Eppendorf Centrifuge 5810R (B. BRAUN, Postfach 1120, 34209 
Melsungen, Germany), pH meter (Beckman Coulter), OLYMPUS IX71 Fluorescence 
Microscope(Olympus Technologies Singapore Pte Ltd, 41 Science Park Road, #04-17/18 
The Gemini, Singapore Science Park II, Singapore), Orbital Shaker 100 (ARMALAB, 
ARMALAB, LLC, Bethesda, MD), Oven, Water Bath (MEMMERT, Memmert 
GmbH+Co.KG, Schwabach, Germany), PowerPac Basic Power Supply 100 (Bio-Rad 
Laboratories, 2000 Alfred Nobel Drive, Hercules, California 94547), Vortex machine 
(VWR Scientific, 1310 Goshen Parkway, West Chester, PA), Ultrasonic Water Bath (ITS 
Science and Medical, 219 Henderson Road, Henderson Industrial Park, Singapore), Blue 
MAXTM 50 ml/15 ml Polypropylene Conical Tube, 1ml/2ml/5ml/10ml/50ml 
nonpyrogenic serological pipet (Becton Dickinson Labware, Becton Dickinson and 
Company, Franklin Lakes, NJ, USA), Fast Turn Cap Mini Poly-QTM Vial (Beckman 
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Coulter, Inc., 4300 N. Harbor Boulevard, Fullerton, CA), MULTIDISH 12 wells, 48 
wells and Easy Flask 75 V/C, 25 V/C (NUNC, Apogent Company, NUNC A/S 
Kamstrupvj.90, Roskilde, Denmark). 
 
2.2. Cell culture 
 
The GM00730A cells were obtained from NIGMS Human Genetic Cell Repository, 
Coriell Institute for Medical Research and maintained in complete EMEM medium at 
37°C in a humidified atmosphere containing 5% CO2. 
 
A new flask was initiated according to following procedure: 
1) The complete EMEM medium was warmed up to 37°C before use. The pipettes 
and culture flasks were irradiated with ultraviolet rays for 30 min in the culture hood. 
2) The cells were removed from liquid nitrogen tank and placed in 37°C water bath 
as soon as possible. After being thawed out, the cells were rapidly transferred into a 25-
cm2 flask. Another 5 ml warm complete EMEM medium was added into the flask. The 
flask was placed in HERA cell CO2 incubator at 37°C in a humidified atmosphere 
containing 5% CO2 overnight. 
3) The medium in the flask was replaced by fresh complete EMEM medium on the 
next day. 




Cells were passaged according to following procedure: 
1) The cells were washed with warm PBS buffer once.  
2) Two ml trypsin-EDTA was added to a 75-cm2 flask for 3 min, and the flask was 
beaten gently to dislodge the cells. 
3) The action of trypsin was stopped with 6 ml complete EMEM medium. The cells 
were resuspended and an appropriate volume was transferred to a new flask, 
which was subsequently added with 15 ml of complete EMEM medium per flask. 
 
Cells were frozen in liquid nitrogen for further usage according to following procedure: 
The subconfluent cells were trypsinised and spun down at 300 ×g for 5 min at room 
temperature. The cell pellet was resuspended in 2 ml frozen medium and stored in NUNC 
Cryo Tube™ vials. The tubes were kept at 4°C for half hour, -20°C for 2 hours, and -
80°C overnight and transferred into liquid nitrogen tank on the following day. 
 
 
2.3. ABCA1 overexpression  
 
2.3.1. ABCA1 overexpression in complete EMEM medium 
 
The cells were seeded in plates in complete EMEM medium. When cells were about 
80%-90% confluence, complete EMEM medium was replaced by complete EMEM 
medium containing 5 µM TO-901317 and further incubated for 24 hours. 
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2.3.2. ABCA1 overexpression in delipidated medium 
 
The cells were seeded in plate in complete EMEM medium. When cells were about 80%-
90% confluence, cells were washed with PBS once and delipidated EMEM medium 
containing 5 µM TO-901317 was added. The cells were incubated for 48 hours in the 
presence of TO-901317. 
 
2.4. Protein determination  
 
Samples for protein determination were prepared according to following procedure: 
1) Culture plate was put on ice. Culture medium was removed from culture wells 
using micropipette. 
2) Two ml ice-cold PBS buffer was used to wash the cells. 
3) Appropriate volume of ice-cold lysis buffer was added to the culture wells. The 
cells were scraped off using cell scraper.  
4) Cell lysate was collected into eppendorf tubes and it was put on ice for 30min. 
Then cell lysate was spun at 13,000 ×g for 10 min at 4°C to remove whole cells 
and nucleus. The post-nuclear supernatant was stored at -20°C for further use. 
 
Protein determination was performed with the Bio Rad RC DC Protein Assay Kit II.  
1) A standard curve (0-1.5 mg BSA/ml) was prepared each time the assay was 
performed. BSA stock solution concentration was 1.5 mg/ml. 
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2) A total of 25 µl of standard BSA solution and the sample were added into clean, 
dry eppendorf tubes. 
3) RC reagent I (125 µl) was added into each tube. The tubes were vortexed and 
incubated for 1 min at room temperature. 
4) RC reagent II (125 µl) was added into each tube. The tubes were vortexed and 
centrifuged at 13,000 ×g for 10 min at room temperature. 
5) The supernatant was discarded by inverting the tubes on clean, absorbent tissue 
paper. Liquid should be dried completely from the tubes. 
6) DC Reagent S (5 µl) was added to each 250 µl of DC Reagent A. This solution 
was then referred to as Reagent A’ and 127 µl Reagent A’ would be required for 
each standard or sample assay (Regent A’ should be prepared freshly. It is stable 
for one week. If precipitate forms, solution should be warmed and vortexed.). 
7) Regent A’ (127 µl) was added to each tube. The tubes were vortexed and 
incubated at room temperature for 5 min or until precipitate is completely 
dissolved. The tubes should be vortexed before proceeding to the next step. 
8) DC Regent B (1 ml) was added to each tube. The tubes were vortexed 
immediately and incubated at room temperature for 15 min. 
9) The liquid was transferred into cuvettes. Absorbance was read at 750 nm. The 
















Fig. 2.1 A typical protein assay standard curve 
 
 
2.5. Western Blotting  
 
Samples for Western Blotting were prepared according to following procedure: 
1) One volume 5×loading buffer was added into 4 volume post-nuclear supernatant 
and vortexed thoroughly.  
2) The samples were boiled at 100°C for 5 min and spun at 13,000×g for 2 min. 
Then the samples were ready for western blotting loading. 
 
Western Blotting was performed according to the well established protocol. Briefly, the 
resolving gel solution (8%) was mixed well and allowed to degas before ammonium 
persulfate (APS) and TEMED were added. All reagents were quickly mixed and poured 
into a mini-gel casting chamber. A depth of 2.0 cm from the top was left empty. The 
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resolving gel was overlaid with water immediately to separate the resolving gel buffer 
from air and was allowed to stay for 30 min. When the resolving gel had solidified, water 
was removed; the stacking gel solution (4%) was prepared and poured on top of the 
resolving gel. A comb was inserted into the stacking gel immediately. The stacking gel 
solution was allowed to stay for 30 min to solidify. After the stacking gel solidified, the 
comb was removed.  
 
Samples (30 µg protein) or 5 µl of precision protein standard were loaded into each well. 
The gel was then electrophoresised at 40 volt when the dye advanced in the stacking gel. 
The voltage was adjusted to 100 volt when the dye entered the resolving gel. The 
electrophoresis was terminated till the dye front ran near the bottom of the resolving gel. 
The resolving gel was isolated from gel casting chamber and soaked in the pre-cooled 
transfer buffer together with the PVDF membrane, sponge and filter paper of the same 
size as the gel for about 10 min. The gel sandwich was stacked in the order of sponge, 
filter paper, gel, membrane, filter paper and sponge. The proteins were transferred from 
gel onto PVDF membrane at 100 volt for 90 min at 4°C. The membrane was then 
blocked in blocking buffer overnight at 4°C or for 1 hour at room temperature with 
shaking. The membrane was then incubated in 10ml of blocking buffer containing 1:500 
diluted anti-ABCA1
 
antibody or 1:1000 diluted anti-actin antibody overnight at 4°C or 
for 1 hour at room temperature with shaking. The membrane was then washed with 
TBST buffer four times to remove the excess first antibody and then incubated in 
blocking buffer containing 1:2000 diluted rabbit anti-goat antibody for detection of 
ABCA1 or 1:5000 diluted anti-mouse antibody for detection of  actin for 1 hour. The 
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membrane was then thoroughly washed with TBST buffer four times to remove the 
excess secondary antibody. Finally the membrane was submerged in a mixture of equal 
volume of super signal west pico chemiluminescent substrate and enhancer. The 
membrane was removed from the mixture and placed against the film in the cassette. The 
film was developed after appropriate exposure by following the manufacturer’s 
instructions.  
 
2.6. Cholesterol efflux 
 
2.6.1. Efflux of plasma membrane derived cholesterol to apoA-I 
 
1) Cells were seeded in 48 well culture plates in complete EMEM medium.   
2) When   about 80%-90% confluence, complete EMEM medium was replaced by 
200 µl complete EMEM medium containing 5 µM TO-901317 to induce 
ABCA1 overexpression. The cells were incubated in the above medium for 24 
hours. 
3) The complete EMEM medium containing 5 µM TO-901317 was then replaced 
by 150 µl serum-free EMEM medium containing 1 µCi 3H-cholesterol and 
cultured for 24 h. 
4) The cells were washed with 37°C PBS containing 0.25% BSA twice and 37°C 
serum-free EMEM medium once. 
5) The cells were incubated in 150 µl serum-free EMEM medium containing 10 
µg/ml apoA-I for indicated time.  
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6) Incubation medium was collected at indicated time point and centrifuged at 
13,000 ×g for 5 min to remove floating cells. 
7) Medium was aliquoted (100 µl) to measure the CPM by liquid scintillation 
counting. 
8) The cells in plates were dissolved in solution containing 0.1 N NaOH and 0.5% 
SDS. The cell lysate was used to measure the CPM of the cells by liquid 
scintillation counting. 
9) The level of cholesterol efflux was calculated as following:  
   Total medium CPM/(total medium CPM + total cellular CPM)×100% 
 
2.6.2. Efflux of plasma membrane derived cholesterol to MβCD 
 
1) Cells were seeded in 48 well culture plates in complete EMEM medium.   
2) When   about 80%-90% confluence, complete EMEM medium was replaced by 
150 µl serum-free EMEM medium containing 1 µCi 3H-cholesterol. The cells 
were labeled for 24 h. 
3) The cells were washed with 37°C PBS containing 0.25% BSA twice and 37°C 
serum-free EMEM medium once. 
4) The cells were incubated in 150 µl serum-free EMEM medium containing 0.1% 
MβCD for indicated time.  
5) Culture medium was collected at indicated time points and centrifuged at 
13,000 ×g for 5 min to remove floating cells. 
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6) Medium was aliquoted (100 µl) to measure the CPM in medium by liquid 
scintillation counting. 
7) The cells in plates were lysed in solution containing 0.1 N NaOH and 0.5% SDS. 
The cell lysate was used to measure the CPM in cells by liquid scintillation 
counting. 
8) The level of cholesterol efflux was calculated as following:  
   Total medium CPM/(total medium CPM + total cellular CPM)×100% 
 
2.6.3. Efflux of de novo synthesized cholesterol to apoA-I 
 
1) Cells were seeded in 12 well culture plates in complete EMEM medium.   
2) When   about 80%-90% confluence, the cells were washed with PBS once. 
Delipidated EMEM medium (1 ml) containing 5 µM TO-901317 was added in 
each well to induce ABCA1 overexpression. The cells were incubated in the 
medium for 48 hours.     
3) The delipidated EMEM medium containing 5 µM TO-901317  was then 
replaced by 500 µl delipidated EMEM medium containing 10 µCi/ml 3H-acetate. 
The cells were cultured for 2 h. 
4) Cells were washed with 37°C PBS containing 0.25% BSA twice and 37°C 
serum-free EMEM medium once. 
5) The cells were incubated in 500 µl serum-free EMEM medium containing 10 
µg/ml apoA-I for indicated time.  
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6) Culture medium was collected at indicated time point and centrifuged at 13,000 
×g for 5 min to remove the floating cells. Supernatant (400 µl) was aliquoted. 
7) The cells in plate were lysed in 500 µl solution containing 0.1 N NaOH and 
0.5% SDS for each well.  
8) The aliquoted medium and the solution containing cell lyses were extracted with 
400 µl hexane:isopropanol (3:2, v/v) for 3 times respectively. The combined 
organic phase was used to measure CPM in medium and cells by liquid 
scintillation counting. 
9) The level of cholesterol efflux was calculated as following:  
   Total medium CPM/(total medium CPM + total cellular CPM)×100% 
 
2.6.4. Efflux of de novo synthesized cholesterol to MβCD 
 
1) Cells were seeded in 12 well culture plates in complete EMEM medium.   
2) When about 80%-90% confluence, the cells were washed with PBS once. 
Delipidated EMEM medium (1 ml) was added into each well. The cells were 
incubated in the medium for 48 hours.     
3) The delipidated EMEM medium was then replaced by 500 µl delipidated 
EMEM medium containing 10 µCi/ml 3H-acetate. The cells were incubated for 
2h. 
4) The cells were washed with 37°C PBS containing 0.25% BSA twice and 37°C 
serum-free EMEM medium once. 
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5) The cells were incubated in 500 µl 0.1% MβCD in serum-free EMEM medium 
for indicated time.  
6) Incubation medium was collected at indicated time point and centrifuged at 
13,000 ×g for 5 min to remove the floating cells. The supernatant (400 µl) was 
aliquoted. 
7) The cells in plates were lysed in 500 µl solution containing 0.1 N NaOH and 
0.5% SDS for each well.  
8) The aliquoted medium and the solution containing cell lyses were extracted with 
400 µl hexane:isopropanol (3:2, v/v) for 3 times respectively. The combined 
organic phase was used to measure CPM in medium and cells by liquid 
scintillation counting. 
9) The level of cholesterol efflux was calculated as following:  
   Total medium CPM/(total medium CPM + total cellular CPM)×100% 
 
2.7. Thin layer Chromatography (TLC) 
 
1) Chamber preparation. Developing solvent was prepared by mixing the 
hexane/ethyl ether/acetic acid (70:30:2, v/v) thoroughly by shaking or vortex. 
Appropriate volume of developing solvent was added into the chamber so that it 
was 0.5 cm deep in the bottom of the chamber. The chamber was sealed and left for 
at least 1 hour so that the atmosphere in the chamber became saturated with the 
developing solvent.  
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2) TLC plate preparation. The TLC plate was cut into appropriate size. A pencil 
was used to draw a line across the plate 1 cm above the bottom of the plate. Under 
the line, light marks were used to indicate the names of the samples. Enough space 
between the samples should be left so that they would not run together, about 4 
samples on a 5 cm wide plate was advised. The plates should be handled carefully 
so that the coating of adsorbent would not be disturbed. The plate was activated at 
100°C for 1 hour before use.  
3) Sample application. Lipid samples were extracted with hexane/isopropanol (3:2, 
v/v) for 3 times and the organic phases were combined together and dried under 
nitrogen flow at room temperature or in freezing dryer. The lipid pellet was 
dissolved in appropriate volume of chloroform/methanol (2:1, v/v). The solution 
was then applied to the TLC plate with a 1 µL microcap. This was done by taking a 
microcap and dipping it into the solution of the sample to be spotted. Then, the end 
of the microcap was gently touched to the adsorbent on the origin in the place 
where marked for the sample. All of the contents of the microcap were let to run 
onto the plate and the spot dried in the air. Care was taken not to disturb the coating 
of the adsorbent.  
4) TLC development. The prepared TLC plate was placed in the developing 
chamber, which was then sealed, and left undisturbed. TLC development was 
stopped when the solvent was about half a centimeter below the top of the plate. 
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5) Visualization of the spots. The TLC plate was taken out of the developing 
chamber and dried in the air. The plate was sprayed with visualizing solvent and 
then heated at 100°C for 5 min immediately after spraying.  
6) Cholesterol analysis. The spot representing cholesterol was scraped off. The 3H 
radioactivity of the spot representing cholesterol and the rest of the lane was 
measured separately. The percentage of 3H-acetate converted into 3H-cholesgerol 
was estimated by: 3H radioactivity in cholesterol / (3H radioactivity in cholesterol + 
3H radioactivity in rest part) ×100%. It has been found that more than 90% of the 
radioactivity was found in 3H-cholesterol. 
 
2.8. Fluorescence Immune Staining 
 
1) Cells were seeded in 24 well culture plates in complete EMEM medium. There 
was a clean cover slip placed in each well.   
2) When cells were about 40%-50% confluence, the complete EMEM medium was 
replaced by serum-free EMEM medium containing 100 nM jasplakinolide or 
1µg/ml cytochalasin D for 24 hours.     
3) The medium was sucked out. The cells were washed with cold PBS for 3 times. 
Then 4% PFA in PBS (0.5 ml) was added into each well for 20 min at room 
temperature to fix the cells. 
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4) PFA was sucked out. The cells were washed with PBS for 3 times. PBS (400 µl) 
containing 0.2% (v/v) Triton-X-100 was added into each well and incubated with 
the cells for 30 min at room temperature. 
5) The PBS containing Triton-X-100 was replaced by 250 µl PBS containing 10 % 
goat serum. The cells were incubated with goat serum for 1 hour. 
6) PBS (200 µl) containing 10% goat serum and 1:250 mouse monoclonal anti-
Actin was added into each well and incubated with cells over night at 4°C. 
7) The cells were washed with PBS for 3 times, each time for 5 min. 
8) PBS (200 µl) containing 10% goat serum and 1:1000 Alexa Fluor® 488 Goat 
anti-mouse IgG was added into each well and incubated with cells for 2 hours at 
room temperature. Plate was wrapped in foil to avoid light.  
9) Cells were washed with PBS 3 times, 5 min for each time. Then the cover slips 
were taken out from each well and mounted with Fluor saveTM Reagent to protect 
the fluorescence in the cells. 










CHAPTER 3. RESULTS 
3.1. Effects of TO-901317 on ABCA1 expression and cholesterol efflux 
3.1.1. Effect of TO-901317 on ABCA1 expression 
TO-901317 is a nonsteroidal ligand of LXR which is known to regulate ABCA1 
expression (Repa et al., 2000). ABCA1 (220 kDa) and β-actin (42 kDa) expression levels 
were determined by Western Blotting. Relatively levels of ABCA1 expression were 
estimated by densitometric analysis and the ratio was calculated. Fig. 3.1 and Fig. 3.2 
show that the density ratios of ABCA1/actin in human fibroblasts treated with 5 µM TO-
901317 were about 70% higher than the rations in control human fibroblasts. The result 
verifies that 5 µM TO-901317 treatment increase ABCA1 protein level about 70% 
whether the cells were cultured in complete EMEM medium or in delipidated EMEM 
medium.      
             ABCA1 (220 kDa)                                              
                                                              
            β-actin (42 kDa)                                            
                                                                  Control                TO-901317 treated 
   Density ratio (ABCA1/actin)        1.01                              1.78     
                                                                              1.78/1.01=1.76 
Fig. 3.1 Effect of TO-901317 on ABCA1 expression in fibroblasts cultured in complete 
EMEM medium. Cells were cultured in complete EMEM medium with or without 5 µM 
TO-901317 for 24 hours and then harvested and ABCA1 protein level was determined by 
Western Blotting. 
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       ABCA1 (220 kDa)                                                  
                                                                     
       β-actin (42 kDa)                                                 
                                                               Control                TO-901317 treated 
   Density ratio (ABCA1/actin)             0.45                            0.76     
                                                                           0.76/0.45=1.69 
 
Fig. 3.2 Effect of TO-901317 on ABCA1 expression in fibroblasts cultured in delipidated 
EMEM medium. Cells were cultured in delipidated EMEM medium with or without 5 




3.1.2. Effect of TO-901317 on cholesterol efflux to apoA -I  
 
Fig. 3.3 and Fig. 3.4 show that cells treated with 5 µM TO-901317 exhibited higher level 
of cholesterol efflux (~ 2.5 fold) when apoA-I was used as the acceptor, whether 3H-
cholesterol was used to label the cells or it was newly synthesized by the cells. The 
increased cholesterol efflux is assumably due to the higher ABCA1 protein level 
expressed in TO-901317 treated cells. These results confirm that ABCA1 plays a very 





































Fig. 3.3 Effect of TO-901317 on efflux of plasma membrane derived cholesterol to apoA-
I. Cells were cultured in complete EMEM medium with or without 5 µM TO-901317 for 
24 hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, 10 
µg/ml apoA-I in serum-free EMEM medium was added to start cholesterol efflux. The 

































Fig. 3.4 Effect of TO-901317 on efflux of de novo synthesized cholesterol to apoA-I. 
Cells were cultured in delipidated EMEM medium with or without 5 µM TO-901317 for 
48 hours and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, 10 
µg/ml apoA-I in serum-free EMEM medium was added to initiate the cholesterol efflux. 
The experiments were performed at 37 °C and each value is the mean ± S.D. of triplicates. 
 
 
The level of cholesterol efflux in control cells is too low and shows no significant change 
over time up to 24 h. In the following experiments, hence, all experiments on cholesterol 
efflux to apoA-I will be performed in cells treated with 5 µM TO-901317, unless 
mentioned otherwise. 
 
3.1.3. Effect of TO-901317 on cholesterol efflux to cyclodextrin 
 
In contrast to apoA-I, when CD was used as the acceptor for cholesterol efflux from the 
fibroblasts, more cholesterol had effluxed from the cells within shorter period of time. 
However, this process appeared independent of ABCA1 as there was no difference in the 






























Fig. 3.5 Effect of TO-901317 on efflux of plasma membrane derived cholesterol to 
MβCD. Cells were cultured in complete EMEM medium with or without 5 µM TO-
901317 for 24 hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After 
washing, 0.1% MβCD in serum-free EMEM medium was added to start the efflux. The 
experiments were performed at 37 °C and each value is the mean ± S.D. of triplicates. 
 
 
3.2. Plasma membrane in cholesterol efflux: role of caveolae 
 
After MβCD treatment, the cellular cholesterol content was reduced by 75% compared 
with that in control cells (Fig. 3.6). Also, such reduction in cellular cholesterol was a 
rapid process and it completed within half hour of MβCD treatment. It is known that 
MβCD may selectively remove cholesterol from membranes and disrupt the structure of 
caveolae. It would be interesting to see if caveolae is involved in cholesterol efflux to 
apoA-I. Fig. 3.7 shows that the level of cholesterol efflux to apoA-I increased up to 4 fold 
when the cells were pre-treated with MβCD. This confirms that caveolae do play a role in 


























Fig. 3.6 Effect of MβCD treatment on cellular cholesterol content. Cells were labeled 
with 1 µCi/ml 3H-cholesterol for 24 hours. After washing with PBS, cells were incubated 
in serum-free EMEM medium with or without 10 mM MβCD for 30 min. Thereafter, the 
medium was removed and the cellular 3H-cholesterol was quantitated with the liquid 
scintillation counter. The experiments were performed at 37 °C and each value is the 































Fig. 3.7 Effect of MβCD extraction on efflux of plasma membrane derived cholesterol to 
apoA-I. Cells were cultured in complete EMEM medium with 5 µM TO-901317 for 24 
hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells 
were incubated in serum-free EMEM medium with or without 10 mM MβCD for 30 min. 
Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to start efflux. The 
medium was collected at indicated time points and the 3H-cholesterol in the medium and 
in the cells was quantitated by liquid scintillation counting. The experiments were 
performed at 37 °C and each value is the mean ± S.D. of triplicates. 
 
 
3.3. Effects of drugs on cholesterol efflux  
 
3.3.1. Brefeldin A 
 
Incubation of BFA with the fibroblasts did not affect the efflux of plasma membrane 
derived cholesterol to apoA-I  (Fig. 3.8). However, the efflux of newly synthesized 
cholesterol to apoA-I was suppressed (Fig. 3.9). These results suggest that cholesterol 
efflux is regulated somehow by its intracellular trafficking. Because BFA is known to 
disrupt the structure and function of Golgi apparatus, the above difference between the 
efflux of plasma membrane cholesterol and the do novo synthesized cholesterol indicates 
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that Golgi apparatus may play a role in cholesterol trafficking from ER to plasma 
membrane. On the other hand, when MβCD was used as the acceptor for cholesterol 
efflux, pre-treatment of the cells with BFA did not affect the efflux whether the 
cholesterol is pre-existing in the cell plasma membrane or newly synthesized (Fig. 3.10 
and Fig. 3.11). These results imply that the de novo synthesized cholesterol may transfer 
from ER to plasma membrane via two separate pathways, the Golgi-dependent pathway 




























Fig. 3.8 Effect of BFA on efflux of plasma membrane derived cholesterol to apoA-I.  
Cells were cultured in complete EMEM medium with 5 µM TO-901317 for 24 hours and 
then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells were 
incubated in serum-free EMEM medium with or without 10 µg/ml BFA for 2 hours. 
Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to start cholesterol 





























Fig. 3.9 Effect of BFA on efflux of de novo synthesized cholesterol to apoA-I. Cells were 
cultured in delipidated EMEM medium with 5 µM TO-901317 for 48 hours and then 
labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, cells were incubated in 
serum-free EMEM medium with or without 10 µg/ml BFA for two hours. Thereafter, 10 
µg/ml apoA-I in serum-free EMEM medium was added to initiate cholesterol efflux. The 





























Fig. 3.10 Effect of BFA on efflux of plasma membrane derived cholesterol to MβCD. 
Cells were labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells were 
incubated in serum-free EMEM medium with or without 10 µg/ml BFA for two hours. 
Thereafter, 0.1% MβCD in serum-free EMEM medium was added to initiate cholesterol 
efflux. The experiments were performed at 37 °C and each value is the mean ± S.D. of 
triplicates. 
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Fig. 3.11 Effect of BFA on efflux of de novo synthesized cholesterol to MβCD. Cells 
were cultured in delipidated EMEM medium for 48 hours and then labeled with 10 
µCi/ml 3H-acetate for 2 hours. After washing, cells were incubated in serum-free EMEM 
medium with or without 10 µg/ml BFA for two hours. Thereafter, 0.1% MβCD in serum-
free EMEM medium was added to initiate cholesterol efflux. The experiments were 





The efflux of plasma membrane derived cholesterol was not affected by nocodazole 
treatment whether the efflux was to apoA-I (Fig. 3.12) or to MβCD (Fig. 3.14). On the 
other hand, the efflux of newly synthesized cholesterol to MβCD was inhibited as much 
as 25% by nocodazole treatment after the efflux was continued for 2h (Fig. 3.15.), while 
the efflux of newly synthesized cholesterol to apoA-I was not inhibited but enhanced 
slightly by nocodazole treatment (Fig. 3.13). As MβCD and apoA-I acquire cholesterol 
from cell surface via different mechanisms and even potentially from different membrane 
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domains, the difference in efflux of newly synthesized cholesterol caused by different 
acceptors implies the existence of independent nascent cholesterol transport pathways, 
with which cholesterol was delivered to different plasma membrane microdomains and 
acquired consequently by different acceptors. From the results obtained, it appears that 































Fig. 3.12 Effect of nocodazole on efflux of plasma membrane derived cholesterol to 
apoA-I.  Cells were cultured in complete EMEM medium with 5 µM TO-901317 for 24 
hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells 
were incubated in serum-free EMEM medium with or without 20 µM nocodazole for two 
hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to initiate 
cholesterol efflux. The experiments were performed at 37 °C and each value is the mean 





























Fig. 3.13 Effect of nocodazole on efflux of de novo synthesized cholesterol to apoA-I. 
Cells were cultured in delipidated EMEM medium with 5 µM TO-901317 for 48 hours 
and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, cells were 
incubated in serum-free EMEM medium with or without 20 µM nocodazole for two 
hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to initiate 
cholesterol efflux. The experiments were performed at 37 °C and each value is the mean 



























Fig. 3.14 Effect of nocodazole on efflux of plasma membrane derived cholesterol to 
MβCD. Cells were labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, 
cells were incubated in serum-free EMEM medium with or without 20 µM nocodazole 
for two hours. Thereafter, 0.1% MβCD in serum-free EMEM medium was added to 
initiate cholesterol efflux. The experiments were performed at 37 °C and each value is the 






























Fig. 3.15 Effect of nocodazole on efflux of de novo synthesized cholesterol to MβCD. 
Cells were cultured in delipidated EMEM medium for 48 hours and then labeled with 10 
µCi/ml 3H-acetate for 2 hours. After washing, cells were incubated in serum-free EMEM 
medium with or without 20 µM nocodazole for two hours. Thereafter, 0.1% MβCD in 
serum-free EMEM medium was added to initiate cholesterol efflux. The experiments 






Jasplakinolide is a drug that promotes and stabilizes actin polymerization (Bubb et al., 
1994). Fig. 3.16 shows that jasplakinolide destabilized the actin microfilaments and 
changed the cells’ morphology dramatically. The fibriform cells became starfish-like. 
Most of the actin subunits concentrated in the center of the cells and a small part of actin 
subunits distributed in the dendrites of the cells. Meanwhile, jasplakinolide increased 
cholesterol efflux to apoA-I whether the cholesterol is derived from plasma membrane or 
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newly synthesized (Fig. 3.17 and Fig.3.18). However, jasplakinolide did not change the 
cholesterol efflux to MβCD regardless of the origin of cholesterol. These results suggest 





             
                          Control cells                                    Jasplakinolide treated cells 
 
Fig. 3.16 Effect of jasplakinolide on polymerization of actin microfilaments. Cells were 
seeded in 24 well plates with clean cover slips. When cells were about 50% confluence, 
complete EMEM medium was replaced by serum-free EMEM medium containing 100 
nM jasplakinolide and incubated for 24 hours. The fluorescence immune staining was 





























Fig. 3.17 Effect of jasplakinolide on efflux of plasma membrane derived cholesterol to 
apoA-I.  Cells were cultured in complete EMEM medium with 5 µM TO-901317 for 24 
hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells 
were incubated in serum-free EMEM medium with or without 100 nM jasplakinolide for 
two hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to 


























Fig. 3.18 Effect of jasplakinolide on efflux of de novo synthesized cholesterol to apoA-I. 
Cells were cultured in delipidated EMEM medium with 5 µM TO-901317 for 48 hours 
and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, cells were 
incubated in serum-free EMEM medium with or without 100 nM jasplakinolide for two 
hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to initiate 





























Fig. 3.19 Effect of jasplakinolide on efflux of plasma membrane derived cholesterol to 
MβCD. Cells were labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, 
cells were incubated in serum-free EMEM medium with or without 100 nM 
jasplakinolide for two hours. Thereafter, 0.1% MβCD in serum-free EMEM medium was 
added to initiate cholesterol efflux. The experiments were performed at 37 °C and each 



























Fig. 3.20 Effect of jasplakinolide on efflux of de novo synthesized cholesterol to MβCD. 
Cells were cultured in delipidated EMEM medium for 48 hours and then labeled with 10 
µCi/ml 3H-acetate for 2 hours. After washing, cells were incubated in serum-free EMEM 
medium with or without 100 nM jasplakinolide for two hours. Thereafter, 0.1% MβCD in 
serum-free EMEM medium was added to initiate cholesterol efflux. The experiments 
were performed at 37 °C and each value is the mean ± S.D. of triplicates. 
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 3.3.4. Cytochalasin D 
 
Cytochalasin D is known to inhibit actin polymerization (Casella et al., 1981). Fig. 3.21 
shows that cytochalasin D completely changed the cells’ morphology and inhibited 
polymerization of actin microfilaments. The fibriform cells became round.  The actin 
subunits distributed in the round cells uniformly. Fig. 3.22 and Fig. 3.23 show that 
cytochalasin D significantly increased cholesterol efflux to apoA-I regardless of the 
cholesterol was derived from the plasma membrane or newly synthesized. However, 
cytochalasin D did not change the cholesterol efflux to MβCD under similar conditions 
(Fig. 3.24 and Fig. 3.25). These results imply that action filaments are involved in 


















         




Fig. 3.21 Effect of cytochalasin D on actin microfilaments. Cells were seeded in 24 well 
plate with clean cover slips. When cells were about 50% confluence, complete EMEM 
medium was replaced by serum-free EMEM medium containing 2 µM cytochalasin D 
and incubated with cells for 24 hours. The fluorescence immune staining was performed 

































Fig. 3.22 Effect of cytochalasin D on efflux of plasma membrane derived cholesterol to 
apoA-I.  Cells were cultured in complete EMEM medium with 5 µM TO-901317 for 24 
hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells 
were incubated in serum-free EMEM medium with or without 2 µM Cytochalasin D for 
two hours. Thereafter 10 µg/ml apoA-I in serum-free EMEM medium was added to 
initiate cholesterol efflux. The experiments were performed at 37 °C and each value is the 

























Fig. 3.23 Effect of cytochalasin D on efflux of de novo synthesized cholesterol to apoA-I. 
Cells were cultured in delipidated EMEM medium with 5 µM TO-901317 for 48 hours 
and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, cells were 
incubated in serum-free EMEM medium with or without 2 µM cytochalasin D for two 
hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was added to initiate 
cholesterol efflux. The experiments were performed at 37 °C and each value is the mean 





























Fig. 3.24 Effect of cytochalasin D on efflux of plasma membrane derived cholesterol to 
MβCD. Cells were labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, 
cells were incubated in serum-free EMEM medium with or without 2 µM cytochalasin D 
for two hours. Thereafter, 0.1% MβCD in serum-free EMEM medium was added to 
initiate cholesterol efflux. The experiments were performed at 37 °C and each value is the 



























Fig. 3.25 Effect of cytochalasin D on efflux of de novo synthesized cholesterol to MβCD. 
Cells were cultured in delipidated EMEM medium for 48 hours and then labeled with 10 
µCi/ml 3H-acetate for 2 hours. After washing, cells were incubated in serum-free EMEM 
medium with or without 2 µM cytochalasin D for two hours. Thereafter 0.1% MβCD in 
serum-free EMEM medium was added to initiate cholesterol efflux. The experiments 
were performed at 37 °C and each value is the mean ± S.D. of triplicates. 
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3.3.5. Deep blue dyed latex beads     
 
To examine if the ER-plasma membrane contacts will affect cholesterol efflux to apoA-I 
or MβCD, the fibroblasts were incubated with 1% deep blue dyed latex beads for 2 hours 
before the efflux was started. The results show that treatment with latex beads did not 
change the cholesterol efflux under any conditions tested. These results indicate that ER-
plasma membrane contacts might not contribute to efflux of cholesterol derived either 






























Fig. 3.26 Effect of deep blue dyed latex beads on efflux of plasma membrane derived 
cholesterol to apoA-I.  Cells were cultured in complete EMEM medium with 5 µM TO-
901317 for 24 hours and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After 
washing, cells were incubated in serum-free EMEM medium with or without 1% deep 
blue dyed latex beads for two hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM 
medium was added to initiate cholesterol efflux. The experiments were performed at 37 





























Fig. 3.27 Effect of deep blue dyed latex beads on efflux of de novo synthesized 
cholesterol to apoA-I. Cells were cultured in delipidated EMEM medium with 5µM TO-
901317 for 48 hours and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After 
washing, cells were incubated in serum-free EMEM medium with or without 1% deep 
blue dyed latex beads for two hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM 
medium was added to initiate the cholesterol efflux. The experiments were performed at 





























Fig. 3.28 Effect of deep blue dyed latex beads on efflux of plasma membrane derived 
cholesterol to MβCD. Cells were labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After 
washing, cells were incubated in serum-free EMEM medium with or without 1% deep 
blue dyed latex beads for two hours. Thereafter, 0.1% MβCD in serum-free EMEM 
medium was added to initiate cholesterol efflux. The experiments were performed at 37 






























Fig. 3.29 Effect of deep blue dyed latex beads on efflux of de novo synthesized 
cholesterol to MβCD. Cells were cultured in delipidated EMEM medium for 48 hours 
and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, cells were 
incubated in serum-free EMEM medium with or without 1% deep blue dyed latex beads 
for two hours. Thereafter, 0.1% MβCD in serum-free EMEM medium was added to 
initiate cholesterol efflux. The experiments were performed at 37 °C and each value is the 





U18666A at nanomolar concentration selectively interferes with cholesterol trafficking to 
the ER without substantively affecting cholesterol transfer to the plasma membrane, 
while micromolar concentration of U18666A inhibits multiple pathways of cholesterol 
trafficking from late endosomes (Underwood et al., 1996). 
 
In order to study the potential effect of such cholesterol intracellular trafficking on 
cholesterol efflux, fibroblasts were treated with 70 nM or 2 µM U18666A before 
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cholesterol efflux was initiated. The results showed in Fig. 3.31-3.33 indicate that efflux 
of cholesterol, whether it was plasma membrane derived or freshly synthesized, was not 
affected when the acceptor as MβCD. However, when apoA-I acted as acceptor, the 
efflux rate was reduced by U18666A for plasma membrane derived cholesterol but not 
the de novo synthesized cholesterol in a doze dependent manner, more retardations being 






























Fig. 3.30 Effect of U18666A on efflux of plasma membrane derived cholesterol to apoA-
I.  Cells were cultured in complete EMEM medium with 5 µM TO-901317 for 24 hours 
and then labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, cells were 
incubated in serum-free EMEM medium without or with 70 nM U18666A or 2 µM 
U18666A for two hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was 
added to initiate cholesterol efflux. The experiments were performed at 37 °C and each 































Fig. 3.31 Effect of U18666A on efflux of de novo synthesized cholesterol to apoA-I. 
Cells were cultured in delipidated EMEM medium with 5 µM TO-901317 for 48 hours 
and then labeled with 10 µCi/ml 3H-acetate for 2 hours. After washing, cells were 
incubated in serum-free EMEM medium without or with 70 nM U18666A or 2 µM 
U18666A for two hours. Thereafter, 10 µg/ml apoA-I in serum-free EMEM medium was 
added to initiate cholesterol efflux. The experiments were performed at 37 °C and each 





























Fig. 3.32 Effect of U18666A on efflux of plasma membrane derived cholesterol to 
MβCD. Cells were labeled with 1 µCi/ml 3H-cholesterol for 24 hours. After washing, 
cells were incubated in serum-free EMEM medium without or with 70 nM U18666A or 2 
µM U18666A for two hours. Thereafter, 0.1% MβCD in serum-free EMEM medium was 
added to initiate cholesterol efflux. The experiments were performed at 37 °C and each 































Fig. 3.33 Effect of U18666A on efflux of de novo synthesized cholesterol to MβCD. 
Cells were cultured in delipidated EMEM medium for 48 hours and then labeled with 10 
µCi/ml 3H-acetate for 2 hours. After washing, cells were incubated in serum-free EMEM 
medium without or with 70 nM U18666A or 2 µM U18666A for two hours. Thereafter, 
0.1% MβCD in serum-free EMEM medium was added to initiate cholesterol efflux. The 











CHAPTER 4. DISCUSSION 
 
4.1. Effect of TO-901317 on ABCA1 expression and cholesterol efflux: 
cholesterol efflux to apoA-I does involve ABCA1 
 
The liver X receptors (LXRs) are members of the nuclear receptor and transcription 
factor superfamily and have two isoforms including LXRα and LXRβ. LXRα is highly 
expressed in liver, intestine, kidney and macrophages. LXRβ is ubiquitously expressed in 
nearly every tissue. Two isoforms of LXRs have a central DNA-binding domain 
consisting of a zinc-finger module and a large ligand-binding domain with a lipophilic 
core that binds specific small lipid molecules. After ligands bind, LXRs form 
heterodimers with the retinoic acid receptor (RXR) which binds to characteristic DNA 
sequence of target genes including ABCA1, ABCG5, ABCG8 and apolipoprotein E 
(apoE). The heterodimers can be activated by ligands for either receptor (Repa and 
Mangelsdorf, 2002).   
 
ABCA1 belongs to the ABC family of genes encoding transmembrane proteins which are 
believed to transport a specific set of molecules across the membrane. ABCA1 is 
believed to play a key role in the transfer of cholesterol and phospholipids to apoA-I, the 
initial step in HDL formation and RCT. Expression of ABCA1 which is dependent on the 
activation of LXR α/β is transcriptionally controlled and increases in response to 
cholesterol loading. However, neither FC nor CE can bind and activate LXRs.  It is 
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speculated that increased intracellular cholesterol induces the production of oxysterols 
that serve as LXR ligands (Repa and Mangelsdorf, 2002). On the other hand, addition of 
oxysterols or synthetic LXR agonists such as TO-901317 induces ABCA1 expression and 
cholesterol efflux independent of cholesterol loading in macrophages (Rowe et al., 2003). 
 
It has been demonstrated that activation of the nuclear receptor LXRα by oxysterol 
ligands up-regulates expression of ABCA1 in mouse NIH 3T3 fibroblasts or RAW264.7 
macrophages. The data also show that ligand activation of LXRα is sufficient to promote 
cholesterol efflux to extracellular acceptor apoA-I through ABCA1 (Venkateswaran et al., 
2000). These results suggest that cellular cholesterol efflux is controlled, at least partly, 
by a nuclear receptor signaling pathway. The ability of oxysterol ligands of LXR to 
stimulate cholesterol efflux is dramatically reduced in Tangier cells with known 
mutations of ABCA1. In addition, treating macrophages with the LXR nonsteroidal 
ligand TO-901317 also induces LXR-dependent up-regulation of ABCA1 expression. 
However, TO-901317 treatment did not affect the intracellular sterol status of these 
macrophages (Repa et al., 2000). The up-regulation of ABCA1 is attributed to the 
presence of a unique DR4 element in the ABCA1 promoter. Activated LXR forms a 
heterodimer with RXR and binds to the DR4 element, activating transcription of the 
ABCA1 gene (Gan et al., 2001).  
 
In this study, treating human fibroblast with TO-901317 increased ABCA1 expression 
and the cholesterol efflux to apoA-I, whether cholesterol was derived directly from the 
plasma membrane or newly synthesized. However, cholesterol efflux to MβCD was not 
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affected. These results have confirmed the previous conclusion, largely obtained in 
macrophage, in human fibroblasts. Furthermore, these results imply that cholesterol 
efflux to MβCD may not be, while cholesterol efflux to apoA-I is clearly ABCA1 
dependent. In other word, ABCA1 does play a key role in cholesterol efflux to apoA-I. 
 
4.2. Role of caveolae in cholesterol efflux  
 
Caveolae are glycosphingolipids/cholesterol rich, clathrin-free plasma membrane 
invaginations with a characteristic diameter of 50 to 100 nm (Smart et al., 1999). The 
core structure of caveolae is enriched in cholesterol, gangliosides, ceramide, 
diacylglycerol (Liu and Anderson, 1995), phosphatidylinositol diphosphate (Pike and 
Casey, 1996), and the integral membrane protein caveolins which are cholesterol binding 
proteins with three isoforms (Murata et al., 1995). Although representing only 1-2% of 
cell plasma membrane, caveolae contain 6-7% of the total cellular cholesterol. If plasma 
membrane contains 90% of the cellular cholesterol, the cholesterol concentration in 
caveolae membranes is 4 to 8-fold higher than the surrounding non-caveolae plasma 
membrane. In living cells, only FC in caveolae was found accessible to filipin and 
cholesterol oxidation (Smart et al., 1994). The properties of this FC pool in caveolae are 
different from those in non-caveolae plasma membrane domains, while have led to the 
hypothesis that caveolae may play a role in cellular cholesterol metabolism. 
 
Previous observations indicate that caveolae play a role in cholesterol transport. (i) 
Caveolin, structure protein of caveolae, is a cholesterol-binding protein (Smart et al., 
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1999). (ii) The nascent cholesterol synthesized in ER first appears in the caveolae domain 
of the plasma membrane and then non-caveolae membrane. It was proposed that the 
newly synthesized cholesterol was transported by a heat-shock multiprotein complex 
consisting of caveolin, heat-shock protein 56, cyclophilin 40, cyclophilin A, and 
cholesterol (Uittenbogaard et al., 1998). (iii) Progesterone, which blocks cholesterol 
transport, causes caveolin accumulation in the lumen of the ER simultaneously (Smart et 
al., 1996). (iv) Cholesterol oxidase treatment causes caveolin to dissociate from plasma 
membrane and redistribute to intracellular vesicles that co-localize with Golgi apparatus 
markers (Smart et al., 1994). (v) The caveolin mRNA levels and caveolin expression and 
cellular FC content are intimately related and may display reciprocal regulation. An 
increase in LDL–FC internalization was associated with proportional cellular FC and up-
regulation of caveolin (Fielding et al., 1997). Depletion of caveolar FC by CD, led to 
down-regulation of caveolin mRNA and cell surface protein levels (Hailstones et al., 
1998). On the other hand, lymphocytes expressing caveolin had a 4.4-fold higher 
concentration of cholesterol in the caveolae fraction and about 4 times higher cholesterol 
transport speed to plasma membrane than control cells lacking caveolin (Smart et al., 
1996). (vi) SR-BI which mediates cholesterol flux between cells and lipoproteins is 
concentrated in caveolae. This suggests that caveolae are the sites in plasma membrane 
for cholesterol exchange (Graf et al., 1999). (vii) ApoA-I (or pre-β-HDL) could bind 
directly to the FC-rich exofacial face of the caveolae and enhance the transport of 
cholesterol to the caveolae in a dose- and time- dependent manner (Sviridov et al., 2001). 
(viii)  When 3H-labeled FC from labeled LDL was selectively transferred into the cells to 
increase cellular FC, the cholesterol concentration in caveolae increased dramatically. 
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Subsequent incubation of these cells with unlabeled native plasma or high density 
lipoprotein selectively unloads FC from such caveolae (Fielding and Fielding, 1995). All 
these studies suggest that caveolae play an essential role in cholesterol metabolism. 
However, the direct evidence about this process is absent. In addition, some data 
available remain controversial, partly due to the different cell types used and the different 
analytical methods adopted.  
 
For instance, it is pointed out that caveolin-1 down-regulation enhanced cellular 
cholesterol efflux (Frank et al., 2001). In such experiments, the cholesterol efflux in cells 
that contained less caveolae could transfer intracellular stored cholesterol to acceptor 
faster via a pathway not involving caveolin-1 compared to control cells. This is 
apparently inconsistent with the results of other studies.   
 
To investigate the role of caveolae in intracellular cholesterol trafficking and efflux in 
human fibroblast, the cells were treated with 10 mM MβCD for 30 min to disrupt 
caveolae structure (Fig. 3.6). Cholesterol depletion by MβCD treatment should cause an 
entire change in the morphology of caveolae. After cholesterol depletion, caveolae 
invaginations might have either disappeared or become shallow with wide openings. 
Immunogold labeling of caveolin showed that the caveolin remained clustered, indicating 
that underlying caveolar structures were still present in the membrane after 50% 
reduction of the amount of plasma membrane cholesterol by 10 mM MβCD treatment, 
perhaps reflecting the existence of flattened caveolar patches or “rafts” in the membrane 
after the extensive but partial cholesterol depletion (Parpal et al., 2001). In this study, it 
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has been found that 10 mM MβCD treatment reduced cellular cholesterol by 75%, 
resulting in increase in cholesterol efflux to apoA-I for about 4 fold. Although the 
cholesterol concentration in caveolae is high, only a small quantity of cholesterol exits in 
the exofacial face of the caveolae. ApoA-I could bind directly to the exofacial face of the 
caveolae to facilitate FC desorption (Saito et al., 1997). In other words, the cholesterol 
concentration on the exofacial face of caveolae partially determinates the rate of the 
cholesterol efflux mediated by apoA-I. Such dramatic increase in cholesterol efflux 
observed in this study may be explained by the following considerations. MβCD 
treatment extracts cholesterol from cell membrane, disrupts caveolae structure and thus 
probably changes the membrane environment of caveolae and surrounding non-caveolae 
membrane. It is hence possible that some cholesterol transfer from cytofacial face of the 
membrane to the exofacial face of the membrane and the higher cholesterol concentration 
on the exofacial face of plasma membrane induces higher cholesterol efflux rate. 
Secondly,   previous study pointed out that sphingomyelin which is rich in caveolae 
preferentially interacts with cholesterol and can decrease sterol transfer between 
membranes. Cells containing less caveolae or reduced sphingomyelin/cholesterol-rich 
plasma domains can transfer cholesterol to an acceptor faster than control cells. In that 
case, cholesterol could be transferred from intracellular cholesterol pool(s) to the plasma 
membrane via a pathway bypassing caveolin-1 (Frank et al., 2001). If this is the case, 
disassembly of caveolae caused by MβCD extraction will free cholesterol from 
sphingomyelin and the cholesterol transport between membranes will be enhanced, 
resulting in higher cholesterol efflux to apoA-I from MβCD-treated fibroblasts compared 
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4.3. How does cholesterol intracellular trafficking affect its efflux? 
 
4.3.1. Golgi apparatus 
 
When cells were labeled with 3H-cholesterol directly, the majority of cellular 3H-
cholesterol was maintained in the plasma membrane and only a minority of cellular 3H-
cholesterol recycled between plasma membrane and cell interior. Although this process is 
inhibited by various drugs, inhibition induced by BFA was not reported. So it is 
reasonable to find that cholesterol efflux was not affected by BFA treatment in cells 
labeled with 3H-cholesterol whether the efflux was to apoA-I or MβCD (Fig. 3.8 and Fig. 
3.10).   
 
It has been reported that Golgi apparatus plays an active role in the movement of LDL-
derived cholesterol from lysosomes to plasma membrane (Coxey et al., 1993). Treatment 
with BFA resulted in enhanced cholesterol delivery to ACAT. This could be due to LDL- 
derived cholesterol destined for the plasma membrane being redistributed to ER by 
blocking the Golgi dependent pathway (Neufeld et al., 1996).  
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On the other hand, newly synthesized cholesterol was found to be transported from ER to 
plasma membrane via a vesicular system (Kaplan and Simoni, 1985). An efficient 
alternative pathway for nascent cholesterol movement was proposed because severe 
disruption of Golgi apparatus did not alter the kinetics of cholesterol arrival at the plasma 
membrane (Urbani and Simoni, 1990). According to this hypothesis, the movement of a 
portion of the newly synthesized cholesterol from ER to plasma membrane occurs by a 
Golgi apparatus-independent pathway. It was reported that newly synthesized cholesterol 
is transported from ER to plasma membrane caveolae for efflux through a heat-shock 
protein-immunophilin chaperone complex consisting of caveolin, heat-shock protein 56, 
cyclophilin 40, cyclophilin A, and cholesterol (Uittenbogaard et al., 1998). Recently, it 
has been found that both raft-poor and raft-rich vesicular transport from the Golgi 
apparatus increased during ABCA1 mediated cholesterol efflux (Zha et al., 2003).  Taken 
together, both Golgi-dependent and –independent pathways may be involved in the 
intracellular cholesterol transport and efflux from ER. 
 
In this study, BFA treatment partly inhibited nascent cholesterol efflux to apoA-I (Fig. 
3.9). This is consistent with the notion that the Golgi apparatus plays an active role in 
cholesterol transport from ER to the plasma membrane sites available for efflux to apoA-
I. Disruption of Golgi by BFA treatment would hamper the trafficking of cholesterol to 
the plasma membrane for efflux. The significance of Golgi-apparatus in cholesterol 
efflux appears only to the process mediated by ABCA1 as efflux of newly synthesized 
cholesterol to MβCD was not affected by BFA treatment (Fig. 3.11).  
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4.3.2. Cytoskeleton  
 
4.3.2.1. Microtubule network 
 
In many cell types, microtubules (MTs) radiate outward from a perinuclear MT-
organizing center (MTOC) and serve as intracellular “highways” along which 
tubulovesicular transport intermediates of the secretory and endocytic pathways travel 
between the cell centre and the plasma membrane. Due to their radial organization in the 
cell and their involvement in membrane transport, MTs are responsible for maintaining 
the normal intracellular locations and organization of the membrane systems such as ER, 
the Golgi apparatus, endosomes and lysosomes (Conrad et al., 1995). So far, the role of 
microtubule in several aspects of cholesterol metabolism has been investigated: 
 
(i). Caveolin cycles between the plasma membrane and the Golgi apparatus through a 
multi-step process. One step, ER/Golgi intermediate compartment (ERGIC)-to-Golgi 
transport, is microtubules-dependent. This bidirectional pathway may indicate roles for 
microtubules in maintaining caveolae and for caveolin in shuttling cholesterol between 
the plasma membrane and the ER/Golgi system (Conrad et al., 1995). 
 
(ii). Are microtubules involved in the transport of LDL-derived cholesterol? Some 
researchers pointed out that disruption of microtubules had no effect on movement of 
LDL-derived cholesterol to ER (Underwood et al., 1998) or plasma membrane (Liscum 
and  Dahl, 1992; Liscum, 1990). On the other hand, the contrary conclusion has also been 
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reported that the transport of intracellular 3H-FC to the cell surface was reduced by 
nocodazole which disrupts microtubules network (Fielding and Fielding, 1996). 
 
(iii). Microtubules play a role in the transport of cholesterol both to and from the 
mitochondria (Crivello and Jefcoate, 1980).  
 
(iv). It has been observed that in intestinal cells the transport of newly synthesized 
cholesterol from ER to the plasma membrane did not require microtubules. These authors 
used cholesterol oxidase to estimate the amount of cholesterol reached the cell surface 
(Field et al., 1998). However, nocodazole treatment inhibited the transport of newly 
synthesized cholesterol to the plasma membrane by about 25% when MβCD was used to 
extract cholesterol from cell surface (Heino et al., 2000).  
 
In this study, the efflux of plasma membrane derived cholesterol was not affected by 
nocodazole treatment whether the efflux was to apoA-I or MβCD (Fig. 3.12 and Fig. 
3.14). However, about 25% of the efflux of newly synthesized cholesterol to MβCD was 
inhibited by nocodazole (Fig. 3.15). This is consistent with the conclusion of Heino et al 
(2000). However, the efflux of newly synthesized cholesterol to apoA-I was not affected 
too much by nocodazole treatment. As MβCD and apoA-I acquire cholesterol from cell 
surface via different mechanisms and may even from different membrane domains; the 
different efflux rate caused by different acceptors may suggest the existence of separate 
intracellular cholesterol transport pathways or cholesterol pools. It appears that the 
transport of cholesterol to the membrane domains which provide cholesterol for efflux to 
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MβCD involves microtubules, while the transport to the domains which provide 
cholesterol for efflux to apoA-I is not affected by microtubules.    
     
4.3.2.2. Actin microfilament 
 
Actin filaments determine the shape of the cells. The dynamic behavior of this network is 
necessary for many of the cell motility processes. Microfilament is a dynamic structure, 
maintained by a rapid and continual exchange of compact and globular subunits between 
the soluble and filamentous forms and this subunit flux is necessary for normal 
cytoskeletal function. Some drugs, such as cytochalasin and jasplakinolide, have a rapid 
and profound effect on the organization of the microfilament in living cells (Alberts et al., 
2002).  
 
The involvement of actin filaments in the transport process was demonstrated by 
treatments of three specific inhibitors, cytochalasins, anti-actin antibodies and DNase I. 
Actin-depolymerizing drug cytochalasin reduced the uptake of 3H-LDL from coated pits 
by an average of 65% at 40 µM, probably by preventing the polymerization of actin into 
microfilaments required for effective invagination (Fielding and Fielding, 1996). It was 
reported that jasplakinolide, which promotes actin polymerization and stabilizes the actin 
filaments (Bubb et al., 1994), inhibited nascent cholesterol transport slightly but 
reproducibly. This inhibition effect was apparently additive with that of BFA, suggesting 
jasplakinolide affected the Golgi-independent cholesterol transport pathway (Lusa et al., 
2003). Disruption of actin filaments in macrophages leads to a specific inhibition of 
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cholesterol esterification. The inhibition effect can not be explained by reduced cellular 
cholesterol content or general inhibitory effects on cholesterol trafficking or the ACAT 
enzyme in these cells. Rather, the data imply that an intact actin cytoskeleton plays a key 
role in the process that occurs specifically when lipoproteins interact with macrophages 
(Tabas et al., 1994). 
 
Further more, actin filaments are essential for caveolae integrity which may play a key 
role in cholesterol trafficking and efflux. Ultrastructural and biochemical analyses have 
indicated an association of caveolae with the actin filaments (Chatenay-Rivauday et al., 
2004). Treatment with actin-depolymerizing drug cytochalasin D or high concentration 
(>5mM) CD increases the mobility of caveolin and caveolae in the plasma membrane. 
Corresponding to the treatment, the number of caveolin located near the cell surface 
declines markedly and caveolae move laterally and cluster in the plane of the membrane.  
These results strongly indicate that both cholesterol and an intact actin cytoskeleton are 
required for the integrity and immobility of caveolae which is very important for 
cholesterol trafficking and efflux (Deurs et al., 2003; Thomsen et al., 2002). 
 
In this study, human fibroblasts were treated with cytocalasin D or jasplakinolide, 
respectively, to investigate the role of actin microfilaments in cholesterol trafficking and 
efflux. As shown in the results, both cytocalasin D (Fig. 3.21) and jasplakinolide (Fig. 
3.16) treatments changed cell morphology dramatically. Most protrusions of the cells 
disappeared and the fibrous network labeled with fluorescence also disappeared. The 
cells treated with cytocalasin D became round and the fluorescence distributed in the cell 
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uniformly. However, the shape of cells treated with jasplakinolide became starfish-like. 
The majority of the fluorescence labeled actin subunits concentrated in the center of the 
cell body and a small part of them distributed in the dendrites of the cells. Both 
cytocalasin D and jasplakinolide did not change cholesterol efflux to MβCD whether 
cholesterol is derived directly from the plasma membrane or from do novo synthesized 
pool. It is interesting to find that both cytocalasin D and jasplakinolide dramatically 
increased cholesterol efflux to apoA-I under similar conditions. In these experiments, the 
nascent cholesterol was synthesized for 2 hours and subsequently treated with the drugs 
for 2 hours at 37°C. Some of the nascent cholesterol may have been transported to the 
plasma membrane at the time when efflux was initiated. Thus, the apparent efflux 
observed may reflect more on the property of the plasma membrane rather than the 
intracellular trafficking. As previously discussed, caveolae play a key role in cholesterol 
trafficking and efflux regulation. Actin filaments and cholesterol are essential for 
caveolae integrity and function (Chatenay-Rivauday et al., 2004). It may therefore be 
assumed that change of caveolae caused by actin filament disruption increased the 
cholesterol efflux to apoA-I. How disruption of caveolae would increase cholesterol 
efflux to apoA-I has been discussed before. Moreover, cholesterol efflux to MβCD did 
not change by treatment with cytocalasin D and jasplakinolide may be explained by its 
non-specific extraction of cholesterol from the cell plasma membrane.    
 
It is noted that both cytocalasin D and jasplakinolide, which affect actin filaments in 
opposite directions, enhanced cholesterol efflux to apoA-I (Fig. 3.17, Fig. 3.18, Fig. 3.22 
and Fig. 3.23). How can cytocalasin D and jasplakinolide have the same effect on 
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cholesterol efflux to apoA-I? The actin cytoskeleton is a dynamic filament network which 
polymerizes and depolymerizes continuously. This dynamic equilibrium is essential for 
multiple cellular functions involving actin filaments. Depolymerizing of actin filaments 
by cytocalasin D or stabilizing of actin filaments by jasplakinolide both change the 
structure and function of the filaments at equilibrium which may explain why both 
cytocalasin D and jasplakinolide increased cholesterol efflux to apoA-I. This explanation 
is supported by the fact that treatment of adipocytes with actin-depolymerizing agent 
cytochalasin D or the actin stabilizing agent jasplakinolide both inhibit insulin-stimulated 
GLUT4 translocation (Kanzaki and Pessin, 2002).   
 
 
4.3.3. Plasma-ER membrane contact 
 
It was pointed out that the movement of newly synthesized cholesterol from ER to 
plasma membrane might occur by a Golgi apparatus-independent pathway although the 
mechanism has not been identified (Urbani and Simoni, 1990). Three candidates have 
been proposed including specialized transport vesicles, transport by soluble sterol-
binding proteins and transport at regions of close apposition of the ER and plasma 
membrane (Prinz, 2000). The third mechanism is suggested by studies on the transport of 
phospholipids to mitochondria, where membrane association between mitochondria and 
the ER of the yeast Saccharomyces cerevisiae is probably required for phospholipid 
translocation between these two organelles (Achleitner et al., 1999).  
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Lusa et al. (2003) demonstrated that promotion of ER-plasma membrane contacts 
induced by latex beads did not affect efflux of nascent cholesterol and prelabeled 
cholesterol to serum in baby hamster kidney (BHK) cells (Lusa et al., 2003). Here I tested 
if ER-plasma membrane contacts would affect the cholesterol efflux in human fibroblast. 
It is consistent to the previous study in BHK cells that latex beads treatment does not 
change the efflux of nascent cholesterol and preexisting cholesterol to apoA-I or MβCD 
(Fig. 3.26 – Fig. 3.29).  From the results, I know that promotion of ER-plasma membrane 
contacts did not affect cholesterol efflux. However, we could not draw the conclusion 
that ER-plasma membrane was not involved in the intracellular cholesterol transport and 
efflux. It is possible that the original ER-plasma membrane contacts without latex beads 
treatment are already sufficient for cholesterol movement from ER to plasma membrane. 
More investigations are needed to verify if ER-plasma membrane contacts play a role in 
cholesterol trafficking and efflux.   
 
 
4.3.4. Effect of U18666A on intracellular cholesterol transport 
 
The pharmacological agent U18666A has been reported to inhibit multiple intracellular 
cholesterol transport pathway. Most studies about U18666A demonstrate that U18666A 
inhibits the transport of LDL-derived cholesterol from late endosomes/lysosomes to 
plasma membrane and causes LDL-derived cholesterol accumulating at high levels in late 
endosomes/lysosomes (Liscum and Faust, 1989). U18666A also inhibits both the basal 
movement of plasma membrane cholesterol to ACAT and the accelerated delivery of 
 86 
plasma membrane cholesterol to ACAT that responds to plasma membrane 
sphingomyelin degradation (Underwood et al., 1996). In addition to affecting the 
transport of cholesterol from the plasma membrane to the ER, U18666A was also 
reported to inhibit the transfer of cholesterol to the mitochondria. In steroidogenic cells, 
cholesterol is used as a precursor for synthesis of steroid hormones and the transport of 
cholesterol to mitochondria plays an important role in the cellular cholesterol 
homeostasis. A time-course study pointed out that the inhibition induced by U18666A of 
plasma membrane cholesterol to cell interior was rapid (within l0-15 min) and reversible 
if U18666A was removed from the incubation mixture (Härmälä et al., 1994). However, 
the mechanism by which U18666A affects various intracellular cholesterol transport 
pathways is unclear.  
 
It was also found that U18666A inhibits cholesterol esterification in ER. This effect is 
probably not a result of a direct inhibition of ACAT activity by U18666A because this 
drug cannot inhibit the esterification of oleoyl-CoA to cholesterol by ACAT in cell-free 
homogenates. It was supposed that the inhibition of cholesterol esterification by 
U18666A arose from the effect of U18666A on cholesterol transfer steps (Härmälä et al., 
1994). On the contrary, Underwood et al. (1996) pointed out that this inhibition involves 
more than the simple retardance of cholesterol movement from lysosomes to the plasma 
membrane and then from the plasma membrane to ER and it must also inhibit a 
previously unknown pathway or a signal event (Underwood et al., 1996). Another 
verified effect of U18666A on cholesterol metabolism is that U18666A reduces 
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cholesterol de novo synthesis dramatically by inhibiting a step in cholesterol synthesis 
distal to HMG-CoA reductase (Chen et al., 1993).  
 
In this study, I treated cells with 70 nM or 2 µM U18666A to examine if different 
concentration of U18666A would affect cholesterol efflux differently. The results show 
that U18666A treatment didnot affect the efflux to MβCD whether the cholesterol is 
plasma membrane-derived or newly synthesized (Fig 3.32 and Fig. 3.33). When apoA-I 
was used as the acceptor, U18666A reduced the efflux of plasma membrane-derived 
cholesterol in a dose-dependent manner, while the efflux of nascent cholesterol was not 
affected significantly.  
 
Underwood et al. (1998) demonstrated that U18666A inhibits movement of FC from late 
endosomes/lysosomes into a cholesterol oxidase accessible pool. Further study pointed 
out that when concentration of U18666A increased, the size of the cholesterol oxidase 
accessible pool of cholesterol decreased (Kellner-Weibel et al., 1999). In living cells, 
only FC in caveolae was found accessible to cholesterol oxidation (Smart et al., 1994). In 
other word, U18666A treatment will reduce the cholesterol concentration in caveolae. 
From previous discussion, we know that cholesterol efflux to apoA-I is closely correlated 
with caveolae. Taken together, it is reasonable that the lower cholesterol concentration in 
caveolae induced by U186666A treatment will reduce cholesterol efflux to apoA-I, as 
observed in this study. However, the mechanism of U18666A treatment is very 
complicated and unclear until now. More investigation is certainly needed in this area. 
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4.5. Summary of cholesterol intracellular cholesterol trafficking and 
cholesterol efflux 
 
To maintain cellular cholesterol homeostasis, HDL or its apolipoproteins remove excess 
FC from cells. This process prevents the excessive accumulation of cholesterol in the 
vessel wall and the development of atherosclerosis. In this study, we investigated the 
mechanism of intracellular cholesterol trafficking and its effect on cholesterol efflux to 
extracellular cholesterol acceptors, namely, apoA-I and MβCD, in human fibroblast. Here, 
the cholesterol for efflux was from two different cholesterol pools: plasma membrane 
derived cholesterol, which was directly labeled with 3H-cholesterol, and de novo 
synthesized cholesterol labeled by using 3H-actate as the precursor. Before cholesterol 
efflux, the cells were treated with different drugs which would affect the microtubules, 
the actin network, the Golgi apparatus and the ER, respectively to examine if these 
factors would contribute to cholesterol trafficking and efflux. 
   
ApoA-I is the main protein of HDL that plays a key role in cholesterol efflux in vivo. 
ApoA-I could bind directly to the exofacial face of the caveolae to facilitate FC 
desorption (Saito et al., 1997). It has been pointed out that apoA-I can stimulate the 
translocation of intracellular cholesterol to the plasma membrane (Oram and Yokoyama, 
1996) and enhance the efflux of intracellular cholesterol (Sviridov and Fidge, 1995). On 
the other hand, MβCD is a non-specific acceptor for cholesterol. It gets cholesterol from 
both caveolae and non-caveolae membrane domains. The results obtained in this study 
confirm that the kinetics of cholesterol effluxes to apoA-I or MβCD were clearly 
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different in most cases, probably due to the fact that apoA-I and MβCD take cholesterol 
from different cholesterol pools. 
 
Also from the results of this study, it is know that caveolae are the key regulator of 
intracellular cholesterol trafficking and efflux. Disassembly of caveolae by cholesterol 
depletion markedly increased the cholesterol efflux. Disruption of actin microfilaments 
which are necessary for caveolae integrity also significantly enhanced cholesterol efflux.  
One of the other conclusions can be drawn through this study is that Golgi apparatus 
appears to play a minor role in the movement of nascent cholesterol from ER to plasma 
membrane. It seems that microtubules, U18666A-inhibited cholesterol intracellular 
trafficking and ER-plasma membrane contacts did not affect cholesterol efflux at any 














Achleitner G., Gaigg B., Krasser A., Kainersdorfer E., Kohlwein S. D., Perktold A., 
Zellnig G., and Daum G. (1999) Association between the endoplasmic reticulum and 
mitochondria of yeast facilitates interorganelle transport of phospholipids through 
membrane contact. Eur J Biochem 264, 545-553 
 
Alberts B., Johnson A., Lewis J., Raff M., Roberts K., and Walter P. (2002) Molecular 
Biology of the Cell 4th edition  
 
Angelin B. (1995) Studies on the regulation of hepatic cholesterol metabolism in humans. 
Eur J Clin Invest 25, 215-224 
 
Babitt J., Trigatti B., Rigotti A., Smart E. J., Anderson R. G. W., Xu S., and Krieger M. 
(1997) Murine SR-B1, a high density lipoprotein receptor that mediates selective lipid 
uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane 
caveolae. J Biol Chem 272, 13242-13249 
 
Blanchette-Mackie E. J. (2000) Intracellular cholesterol trafficking: role of the NPC1 
protein. Biochim Biophys Acta 1486, 171-183  
 
Brasaemle D. L. and Attie A. D. (1990) Rapid intracellular transport of LDL-derived 
cholesterol to the plasma membrane in cultured fibroblasts. J Lipid Res 31, 103-112 
 
Brooks-Wilson A., Marcil M., Clee S. M., Zhang L. H., Roomp K., van Dam M., Yu. L., 
Brewer C., Collins J. A., Molhuizen H. O. F., Loubser O., Ouelette B. F. F., Fichter K., 
Ashbourne-Excoffon K. J. D., Sensen C. W., Scherer S., Mott S., Denis M., Martindale 
D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J. J. P., Genest J. Jr and 
Hayden M. R. (1999) Mutations in ABC1 in Tangier disease and familial high-density 
lipoprotein deficiency. Nat Genet 22, 336-345. 
 
Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W., 
Barlage S., Büchler C., Porsch-Özcürümez M., Kaminski W. E., Hahmann H. W., Oette 
K., Rothe G., Aslanidis C., Lackner K. J. and Schmitz G. (1999) The gene encoding 
ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22, 347-351 
 
Brown M. S. and Goldstein J. L. (1980) Multivalent feedback regulation of HMG CoA 
reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J 
Lipid Res 21, 505-517 
 
Brown M. S. and Goldstein J. L. (1986) A receptor-mediated pathway for cholesterol 
homeostasis. Science 232, 34-47 
 
Bubb M. R., Senderowicz A. M. J., Sausville E. A., Duncan K. L. K., and Korn E. D. 
(1994) Jasplakinolide, a cytotoxic natural product, induces actin polymerization and 
competively inhibits the binding of phalloidin to F-actin. J Biol Chem 269, 14869-14871 
 91 
Butler J. D., Blanchette-Mackie J., Goldin E., O'Neill R. R., Carstea G., Roff C. F., 
Patterson M. C., Patel S., Comly M. E., Cooney A., Vanier M. T., Brady R. O., and 
Pentchev P. G . (1992) Progesterone blocks cholesterol translocation from lysosomes. J 
Biol Chem 267, 23797-23805. 
 
Casella J. F., Flanagan M. D., and Lin S. (1981) Cytochalasin D inhibits actin 
polymerization and induces depolymerization of actin filaments formed during platelet 
shape change. Nature 293, 302-305 
 
Chambenoit O., Hamon Y., Marguet D., Rigneault H., Rosseneu M. and Chimini G. 
(2001) Specific docking of apolipoprotein A-I at the cell surface requires a functional 
ABCA1 transporter. J Biol Chem 276, 9955-9960   
 
Chang T.Y., Chang C. C.Y., and Cheng D. (1997) Acyl coenzyme A: cholesterol 
acyltransferase. Annu Rev Biochem 66, 613-638 
 
Chao W. T., Fan S. S., Chen J. K., and Yang V. C. (2003) Visualizing caveolin-1 and 
HDL in cholesterol-loaded aortic endothelial cells. J Lipid Res 44, 1094-1099 
 
Chatenay-Rivauday C., Cakar Z. P., Jenö P., Kuzmenko E. S., and Fiedler K. (2004) 
Caveolae: biochemical analysis. Molecular Biology Reports 31, 67-84 
 
Chen H., Born E., Mathur S. N., and Field F. J. (1993) Cholesterol and sphingomyelin 
syntheses are regulated independently in cultured human intestinal cells, CaCo-2: role of 
membrane cholesterol and sphingomyelin content. J Lipid Res 34, 2159-2167 
 
Chinetti G., Lestavel S., Bocher V., Remaley A. T., Neve B., Torra I. P., Teissier E., 
Minnich A., Jaye M., Duverger N., Brewer H. B., Fruchart J. C., Clavey V., and Staels B. 
(2001) PPAR-α and PPAR-γ activators induce cholesterol removal from human 
macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7, 53-58 
 
Conrad P. A., Smart E. J., Ying Y. S., Anderson R. G., and Bloom G. S. (1995) Caveolin 
cycles between plasma membrane caveolae and the Golgi complex by microtubule-
dependent and microtubule-independent steps. J Cell Biol 131, 1421-1433 
 
Coxey R. A., Pentchev P. G., Campbell G., and Blanchette-Mackie E. J. (1993) 
Differential accumulation of cholesterol in Golgi compartments of normal and Niemann-
Pick type C fibroblasts incubated with LDL: a cytochemical freeze-fracture study. J Lipid 
Res 34, 1165-1176 
 
Crivello J. F. and Jefcoate C. R. (1980) Intracellular movement of cholesterol in rat 
adrenal cells. Kinetics and effects of inhibitors. J Biol Chem 255, 8144-8151 
 
Daniel J. R. MD. (2003) Regulation of reverse cholesterol transport and clinical 
implications. Am J Cardiol 92(suppl), 42J-49J 
 
 92 
Dean M., Hamon Y., and Chimini G. (2001) The human ATP-binding cassette (ABC) 
transporter superfamily. J Lipid Res 42, 1007-1017 
 
de la Llera-Moya M., Connelly M. A., Drazul D., Klein S. M., Favari E., Yancey P. G., 
Williams D. L., and Rothblat G. H. (2001) Scavenger receptor class B type I affects 
cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J Lipid 
Res 42, 1969-1978 
 
de la Llera-Moya M., Rothblat G. H., Connelly M. A., Kellner-Weibel G., Sakr S. W., 
Phillips M. C., and Williams D. L. (1999) Scavenger receptor BI (SR-BI) mediates free 
cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40, 575-
580 
 
DeGrella R. F. and Simoni R.D. (1982) Intracellular transport of cholesterol to the 
plasma membrane. J Biol Chem 257, 14256-14262 
 
Deurs B. V., Roepstorff K., Hommelgaard A. M., and Sandvig K. (2003) Caveolae: 
anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 13, 92-100 
 
Dietschy J. M., Turley S. D., and Spady D.K. (1993) Role of liver in the maintenance of 
cholesterol and low density lipoprotein homeostasis in different animal species including 
humans. J Lipid Res 34, 1637-1659 
 
Evans R. M. (1994) Intermediate filaments and lipoprotein cholesterol. Trends Cell Biol 
4, 149-151 
 
Field F. J., Born E., Murthy S., and Mathur S. N. (1998) Transport of cholesterol from 
the endoplasmic reticulum to the plasma membrane is constitutive in CaCo-2 cells and 
differs from the transport of plasma membrane cholesterol to the endoplasmic reticulum. 
J Lipid Res 39, 333-343 
 
Fielding C. J., Bist A., and Fielding P. E. (1997) Caveolin mRNA levels are up-regulated 
by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl 
Acad Sci U S A 94, 3753-3758 
 
Fielding C. J. and Fielding P. E. (1997) Intracellular cholesterol transport. J Lipid Res 38, 
1503-1521 
 
Fielding C. J. and Fielding P. E. (2001) Cellular cholesterol efflux. Biochim Biophys Acta 
1533, 175-189 
 
Fielding P. E., and Fielding C. J., (1996) Intracellular transport of low density lipoprotein 
derived free cholesterol begins at clathrin-coated pits and terminates at cell surface 
caveolae. Biochemistry 35, 14932-14938. 
 
 93 
Fielding P. E. and Fielding C. J. (1995) Plasma membrane caveolae mediate the efflux of 
cellular free cholesterol. Biochemistry 34, 14288-14292 
 
Fielding P. E., Nagao K., Hakamata H., Chimini G., and Fielding C.J. (2000) A two-step 
mechanism for free cholesterol and phospholipid efflux from human vascular cells to 
apolipoprotein A-I. Biochemistry 39, 14113-14120 
 
Fitzgerald M. L., Morris A. L., Rhee J. S., Andersson L. P., Mendez A. J. and Freeman M. 
W. (2002) Naturally occurring mutations in the largest extracellular loops of ABCA1 can 
disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 277, 33178-33187 
 
Francis G. A., Knopp R. H., and Oram J. F. (1995) Defective removal of cellular 
cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest 96, 
78-87 
 
Frank P. G., Galbiati F., Volonte D., Razani B., Cohen D. E., Marcel Y. L., and Lisanti M. 
P. (2001) Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density 
lipoproteins. Am J Physiol Cell Physiol 280, C1204-C1214  
 
Fredrickson D. S. (1964) The inheritance of high density lipoprotein deficiency (Tangier 
disease). J Clin Invest 43, 228-236    
 
Fu Y., Hoang A., Escher G., Parton R. G., Krozowski Z., and Sviridov D. (2004) 
Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J Biol Chem 279, 
14140-14146 
 
Gan X., Kaplan R., Menke J. G., MacNaul K., Chen Y., Sparrow C. P., Zhou G., Wright 
S. D., and Cai T. Q. (2001) Dual mechanisms of ABCA1 regulation by geranylgeranyl 
pyrophosphate. J Biol Chem 276, 48702-48708 
 
Gillotte K. L., Davidson W. S., Lund-Katz S., Rothblat G. H., and Phillips M. C. (1998) 
Removal of cellular cholesterol by pre-β-HDL involves plasma membrane 
microsolubilization. J Lipid Res 39, 1918-1928  
 
Gillotte K. L., Zaiou M., Lund-Katz S., Anantharamaiah G. M., Holvoet P., Dhoest A., 
Palgunachari M. N., Segrest J. P., Weisgraber K. H., Rothblat G. H., and Phillips M. C. 
(1999) Apolipoprotein-mediated plasma membrane microsolubilization: role of lipid 
affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. 
J Biol Chem 274, 2021-2028 
 
Glomset, J. A. (1968) The plasma lecithin:cholesterol acyltransferase reaction. J Lipid 
Res 9,155-167 
 
Graf G. A., Connell P. M., van der Westhuyzen D. R., and Smart E. J. (1999) The class B, 
type I scavenger receptor promotes the selective uptake of high density lipoprotein 
cholesterol ethers into caveolae. J Biol Chem 274, 12043-12048 
 94 
Graf G. A., Matveev S. V., and Smart E. J. (1999) Class B scavenger receptors, caveolae 
and cholesterol homeostasis. Trends Cardiovasc Med 9, 221-225 
 
Hailstones D., Sleer L. S., Parton R. G., and Stanley K. K. (1998) Regulation of caveolin 
and caveolae by cholesterol in MDCK cells. J Lipid Res 39, 369-379 
 
Härmälä Ann-Sofi., Isabella Pörn M., Mattjus P., and Slotte J. P. (1994) Cholesterol 
transport from plasma membranes to intracellular membranes is inhibited by 3β-[2-
(diethylamino) ethoxy]androst-5-en-17-one. Biochim Biophys Acta 1211, 317-325 
 
Härmälä A-S., Isabella Pörn M., and Slotte J. P. (1993) Sphingosine inhibits 
sphingomyelinase-induced cholesteryl ester formation in cultured fibroblasts. Biochim 
Biophys Acta 1210, 97-104 
 
Heino S., Lusa S., Somerharju P., Ehnholm C., Olkkonen V. M., and Ikonen E. (2000) 
Dissecting the role of the Golgi complex and lipid rafts in biosynthetic transport of 
cholesterol to the cell surface. Proc Natl Acad Sci U S A 97, 8375-8380 
 
Horton J. D., Goldstein J. L., Brown M. S. (2002) SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109, 1125-1131 
 
Ikonen E. (2001) Roles of lipid rafts in membrane transport. Curr Opin Cell Biol 13, 470-
477 
 
Ji Y., Jian B., Wang N., Sun Y., Moya M. L., Phillips M. C., Rothblat G. H., Swaney J. 
B., and Tall A. R. (1997) Scavenger receptor B1 promotes high density lipoprotein-
mediated cellular cholesterol efflux. J Biol Chem 272, 20982-20985 
 
Jian B, de la Llera-Moya M., Ji Y., Wang N., Phillips M. C., Swaney J. B., Tall A. R., 
and Rothblat G. H. (1998) Scavenger receptor class B type I as a mediator of cellular 
cholesterol efflux to lipoproteins and phospholipid acceptors. J Biol Chem 273, 5599-
5606 
 
Johnson W. J., Chacko G. K., Philips M. C., and Rothblat G.H. (1990) The efflux of 
lysosomal cholesterol from cells. J Biol Chem 265, 5546-5553 
 
Johnson W. J., Mahlberg F. H., Rothblat G. H., and Phillips M. C. (1991) Cholesterol 
transport between cells and high-density lipoproteins. Biochim Biophys Acta 1085, 273-
298 
 
Kanzaki M. and Pessin J. E. (2002) Caveolin-associated filamentous actin (Cav-actin) 
defines a novel F-actin structure in adipocytes. J Biol Chem 277, 25867-25869 
 
Kaplan M. R. and Simoni R.D. (1985) Transport of cholesterol from the endoplasmic 
reticulum to the plasma membrane. J Cell Biol 101, 446-453 
 95 
 Kellner-Weibel G., de la Llera-Moya M., Connelly M. A., Stoudt G., Christian A. E., 
Haynes M. P., Williams D. L., and Rothblat G. H. (2000) Expression of scavenger 
receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry 39, 
221-229 
 
Kellner-Weibel G., Geng Y. J., and Rothblat G. H. (1999) Cytotoxic cholesterol is 
generated by the hydrolysis of cytoplasmic cholesteryl ester and transported to the plasma 
membrane. Atherosclerosis 146, 309-319 
 
Kellner-Weibel G., Luke S. J., and Rothblat G. H. (2003) Cytotoxic cellular cholesterol is 
selectively removed by apoA-I via ABCA1. Atherosclerosis 171, 235-243 
 
Knight B.L. (2004) ATP-binding cassette transporter A1: regulation of cholesterol efflux. 
Biochem Soc Trans 32, 124-127 
 
Krieger M. (1999) Charting the fate of the “good cholesterol”: identification and 
characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 68, 
523-558 
 
Lange Y. (1994) Cholesterol movement from plasma membrane to rough endoplasmic 
reticulum. J Biol Chem 269, 3411-3414 
 
Lange Y., Strebel F., and Steck T. L. (1993) Role of the plasma membrane in cholesterol 
esterification in rat hepatoma cells. J Biol Chem 268, 13838-13843 
 
Lange Y., Ye J., Rigney M., and Steck T. L. (1999) Regulation of endoplasmic reticulum 
cholesterol by plasma membrane cholesterol. J Lipid Res 40, 2264-2270 
 
Liscum L. and Munn N. J. (1999) Intracellular cholesterol transport. Biochim Biophys 
Acta 1438, 19-37 
 
Langmann T., Klucken J., Reil M., Liebisch G., Luciani M. F., Chimini G., Kaminski W. 
E., and Schmitz G. (1999) Molecular cloning of the human ATP-binding cassette 
transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. 
Biochem Biophys Res Commun 257, 29-33 
 
Lin G. and Oram J. F. (2000) Apolipoprotein binding to protruding membrane domains 
during removal of excess cellular cholesterol. Atherosclerosis 149, 359-370 
 
Liscum L. (1990) Pharmacological inhibition of the intracellular transport of low-density 
lipoprotein-derived cholesterol in Chinese hamster ovary cells. Biochim Biophys Acta 
1045, 40-48 
 
Liscum L. and Dahl N. K. (1992) Intracellular cholesterol transport. J Lipid Res 33, 
1239-1254   
 
 96 
Liscum L. and Faust J. R. (1989) The intracellular transport of low density lipoprotein-
derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3- beta-[2-
(diethylamino)ethoxy]androst-5-en-17-one. J Biol Chem 264, 11796-11806 
 
Liscum L. and Munn N. J. (1999) Intracellular cholesterol transport. Biochim Biophys 
Acta 1438, 19-37  
 
Liu P. and Anderson R. G. W. (1995) Compartmentalized production of ceramide at the 
cell surface. J Biol Chem 270, 27179-27185 
 
Lusa S., Heino S., and Ikonen E. (2003) Differential mobilization of newly synthesized 
cholesterol and biosynthetic sterol precursors from cells. J Biol Chem 278, 19844-19851 
 
Mendez A. J. and Uint L. (1996) Apolipoprotein-mediated cellular cholesterol and 
phospholipid efflux depend on a functional Golgi apparatus. J Lipid Res 37, 2510-2524 
 
Michael L. F., Kei-ichiro O., Short G. F. III, Manning J. J., Bell S. A., and Freeman M. 
W., (2004) ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA 
motif that is required for its cholesterol efflux and apoA-I binding activities. J Biol Chem 
279, 48477-48485 
 
Millard E. E., Srivastava K., Traub L. M., Schaffer J. E., and Ory D. S. (2000) Niemann-
Pick Type C1 (NPC1) overexpression alters cellular cholesterol homeostasis. J Biol 
Chem 275, 38445-38451 
 
Mukherjee S., Zha X., Tabas I., and Maxfield F. (1998) Cholesterol distribution in living 
cells: fluorescence imaging using dehydroergosterol as a fluorescent cholesterol analog. 
Biophys J 75, 1915-1925 
 
Murata M., Peranen J., Schreiner R., Wieland F., Kurzchalia T. V., and Simons K. (1995) 
VIP21/Caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 92, 10339-
10343 
 
Neufeld E. B., Cooney A. M., Pitha J., Dawidowicz E. A., Dwyer N. K., Pentchev P. G., 
and Blanchette-Mackie E. J. (1996) Intracellular trafficking of cholesterol monitored with 
a cyclodextrin. J Biol Chem 271, 21604-21613 
 
Oram J. F., Lawn R. M., Garvin M. R., and Wade D. P. (2000) ABCA1 is the cAMP-
inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. 
J Biol Chem 275, 34508-34511 
 
Owen J. S. and Mulcahy J. V. (2002) ATP-binding cassette A1 protein and HDL 
homeostasis. Atheroscler Supp 3, 13-22 
 
 97 
Panousis C. G. and Zuckerman S. H. (2000) Interferon-gamma induces downregulation 
of Tangier disease gene (ATP- binding-cassette transporter 1) in macrophage-derived 
foam cells. Arterioscler Thromb Vasc Biol 20, 1565-1571 
 
Parpal S., Karlsson M., Thorn H., and Stralfors P. (2001) Cholesterol depletion disrupts 
caveolae and insulin receptor signaling for metabolic control via insulin receptor 
substrate-1, but not for mitogen-activated protein kinase control. J Biol Chem 276, 9670-
9678 
 
Pentchev P. G., Brady R. O., Blanchette-Mackie E. J., Vanier M. T., Carstea E. D., 
Parker C. C., Goldin E., and Roff C. F.  (1994) The Niemann-Pick C lesion and its 
relationship to the intracellular distribution and utilization of LDL cholesterol. Biochim 
Biophys  Acta 1225, 235-243  
 
Pike L. J. and Casey L. (1996) Localization and turnover of phosphatidylinositol 4,5-
bisphosphate in caveolin-enriched membrane domains. J Biol Chem 271, 26453-26456 
 
Phillips M. C., Johnson W. J., and Rothblat G. H. (1987) Mechanisms and consequences 
of cellular cholesterol exchange and transfer. Biochim Biophys Acta 906, 223-276 
 
Pittman R. C., Knecht T. P., Rosenbaum M. S., and Taylor, C. A. J. (1987) A 
nonendocytotic mechanism for the selective uptake of high density lipoprotein-associated 
cholesterol esters. J Biol Chem 262, 2443-2450. 
 
Pohl P., Saparaov S. M., and Antonenko Y. N. (1998) The size of the unstirred layer as a 
function of the solute diffusion coefficient. Biophys J 75, 1403-1409 
 
Prinz W. (2002) Cholesterol trafficking in the secretory and endocytic systems. Semin 
Cell Dev Biol 13, 197-203 
 
Raggers R. J., Pomorski T., Holthuis J. C. M., Kälin N., and Meer G. (2000) Lipid traffic: 
the ABC of transbilayer movement. Traffic 1, 226-234 
 
Repa J. J. and Mangelsdorf  D. J. (2002) The liver X receptor gene team: potential new 
players in atherosclerosis. Nat Med 8, 1243-1248 
 
Repa J. J., Turley S. D., Lobaccaro J. A.  Medina J., Li L., Lustig K., Shan B., Heyman R. 
A., Dietschy J. M., and Mangelsdorf D. J. (2000) Regulation of absorption and ABC1-
mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529 
 
Rodriguez-Lafrasse C., Rousson R., Bonnet J., Pentchev P. G., Louisot P., and Vanier M. 
T. (1990) Abnormal cholesterol metabolism in imipramine-treated fibroblast cultures. 
Similarities with Niemann-Pick type C disease. Biochim Biophys Acta 1043, 123-128 
 
 98 
Rothblat G. H., Llera-Moya M., Atger V., Kellner-Weibel G., Williams D. L., and 
Phillips M. C. (1999) Cell cholesterol efflux: integration of old and new observations 
provides new insights. J Lipid Res 40, 781-796 
 
Rothblat G. H. and Phillips M. C. (1982) Mechanism of cholesterol efflux from cells 
effects of acceptor structure and concentration.  J Biol Chem 257, 4775-4782 
 
Rowe A. H., Argmann C. A., Jane Y., Edwards J. Y., Sawyez C. G., Morand O. H., 
Hegele R. A., and Huff M. W. (2003) Enhanced synthesis of the oxysterol 24(S),25-
epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a 
novel mechanism for the attenuation of foam cell formation. Circ Res 93, 717-725 
 
Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze J. F., Brewer H. B., 
Duverger N., Denèfle P. and Assmann G. (1999) Tangier disease is caused by mutations 
in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22, 352-355 
 
Sasahara T., Nestel P., Fidge N., and Sviridov D. (1998) Cholesterol transport between 
cells and high density lipoprotein subfractions from obese and lean subjects. J Lipid Res 
39, 544-554 
 
Saito H., Miyako Y., Handa T., and Miyajima K. (1997) Effect of cholesterol on 
apolipoprotein A-1 binding to lipid bilayers and emulsions. J Lipid Res 38, 287-294 
 
Schroeder F, Gallegos A. M., Atshaves B. P., Storey S. M., McIntosh A. L., Petrescu A. 
D., Huang H., Starodub O., Chao H., Yang H., Frolov A., Kier A. B. (2001) Recent 
advances in membrane microdomains: rafts, caveolae, and intracellular cholesterol 
trafficking. Exp Biol Med 226, 873-890 
 
Simons K. and Ikonen E. (1997) Functional rafts in cell membranes. Nature 387, 569-572 
 
Skiba P. J., Zha X., Maxfield F. R., Schissel S. L., and Tabas I. (1996) The distal 
pathway of lipoprotein-induced cholesterol esterification, but not sphingomyelinase-
induced cholesterol esterification, is energy-dependent. J Biol Chem 271, 13392-13400 
 
Smart E. J., Graf G. A., McNiven M. A., Sessa W. C., Engelman J. A., Scherer P. E., 
Okamoto T., and Lisanti M. P. (1999) Caveolins, liquid-ordered domains, and signal 
transduction. Mol Cell Biol 19, 7289-7304 
 
Smart E. J., Ying Y. S., Conrad P. A., and Anderson R. G. W. (1994) Caveolin moves 
from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol 127, 
1185-1197 
 
Smart E. J., Ying Y. S., Donzell W. C., and Anderson R. G. W., (1996) A Role for 
Caveolin in Transport of Cholesterol from Endoplasmic Reticulum to Plasma Membrane. 
J Biol Chem 271, 29427-29435 
 
 99 
Stocker R. and Keaney J. F., JR. (2004) Role of oxidative modifications in 
atherosclerosis. Physiol Rev 84, 1381-1478  
 
Sviridov D. and Fidge N. (1995) Efflux of intracellular versus plasma membrane 
cholesterol in HepG2 cells: different availability and regulation by apolipoprotein A-I. J 
Lipid Res 36, 1887-1896 
 
Sviridov D., Fidge N., Beaumier-Gallon G., and Fielding C. (2001) Apolipoprotein A-I 
stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich 
domains (caveolae). Biochem J 358, 79-86 
 
Sviridov D. and Nestel P. (2002) Dynamics of reverse cholesterol transport: protection 
against atherosclerosis. Atherosclerosis 161, 245-254 
 
Tabas I., Zha X., Beatini N., Myers J. N., and Maxfield F. R. (1994) The actin 
cytoskeleton is important for the stimulation of cholesterol esterification by atherogenic 
lipoproteins in macrophages. J Biol Chem 269, 22547-22556 
 
Tall A. R. (1990) Plasma high density lipoproteins metabolism and relationship to 
atherogenesis. J Clin Invest 86, 379-384 
 
Thomsen P., Roepstorff K., Stahlhut M., and Deurs B. V., (2002) Caveolae are highly 
immobile plasma membrane microdomains, which are not involved in constitutive 
endocytic trafficking. Mol Biol Cell 13, 238-250 
 
Yancey P. G., Bortnick A. E., Kellner-Weibel G., Llera-Moya M., Phillips M. C., 
Rothblat G. H., (2003) Importance of different pathways of cellular cholesterol efflux. 
Arterioscler Thromb Vasc Biol 23, 712-719 
 
Uittenbogaard, A., Ying, Y.S., and Smart, E. J., (1998) Characterization of a cytosolic 
heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J 
Biol Chem 273, 6525-6532 
 
Underwood K. W., Andemariam B., McWilliams G. L., and Liscum L. (1996) 
Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol 
transport. J Lipid Res 37, 1556-1568 
 
Underwood K. W., Jacobs N. L., Howley A., and Liscum L. (1998) Evidence for a 
cholesterol transport pathway from lysosomes to endoplasmic reticulum that is 
independent of the plasma membrane. J Biol Chem 273, 4266-4274 
 
Urbani L. and Simoni R. D. (1990) Cholesterol and vesicular stomatitis virus G protein 
take separate routes from the endoplasmic reticulum to the plasma membrane. J Biol 
Chem 265, 1919-1923 
 
 100 
Vedhachalam C., Liu L., Nickel M., Dhanasekaran P., Anantharamaiah G. M., Lund-Katz 
S., Rothblat G. H., and Phillips M. C. (2004) Influence of ApoA-I structure on the 
ABCA1-mediated efflux of cellular lipids. J Biol Chem 279, 49931-49939 
 
Venkateswaran A., Laffitte B. A., Joseph S. B., Mak P. A., Wilpitz D. C., Edwards P. A. 
and Tontonoz P.  (2000) Control of cellular cholesterol efflux by the nuclear oxysterol 
receptor LXRα. Proc Natl Acad Sci U S A 97, 12097-12102 
 
Walker J. E., Saraste M., Runswick M. J., and Gay N. J. (1982) Distantly related 
sequences in the α- and β-subunits of ATP synthase, myosin, kinases and other ATP-
requiring enzymes and a common nucleotide binding fold. EMBO J 1, 945-951 
 
Wang N., Silver D. L., Costet P. and Tall A. R. (2000) Specific Binding of ApoA-I, 
Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells 
Expressing ABC1. J Biol Chem 275, 33053-33058 
 
Wang N., Silver D. L., Thiele C., and Tall A. R. (2001) ATP-binding cassette transporter 
A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 276, 
23742-23747 
 
Zha X., Gauthier A., Genest J., and McPherson R.  (2003) Secretory vesicular transport 
from the Golgi is altered during ATP-binding cassette protein A1 (ABCA1)-mediated 
cholesterol efflux. J Biol Chem 278, 10002-10005 
 
 
 
 
 
 
 
 
 
 
 
 
